Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:organic hydride
go back to main search page
Accession:CHEBI:37175 term browser browse the term
Synonyms:related_synonym: organic hydrides


show annotations for term's descendants           Sort by:
 
(24S)-24-hydroxycholesterol term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCA1 ATP binding cassette subfamily A member 1 affects localization
increases expression
EXP 24-hydroxycholesterol affects the localization of ABCA1 protein
24-hydroxycholesterol results in increased expression of ABCA1 mRNA
CTD PMID:16530456 NCBI chr 1:246,144,277...246,278,492
Ensembl chr 1:246,144,277...246,278,492
JBrowse link
G APOA1 apolipoprotein A1 multiple interactions
increases secretion
EXP 24-hydroxycholesterol promotes the reaction [APOA1 protein results in increased transport of Cholesterol]
24-hydroxycholesterol results in increased secretion of APOA1 protein
CTD PMID:16530456 NCBI chr 9:44,216,481...44,218,360
Ensembl chr 9:44,216,393...44,218,978
JBrowse link
G CYP7A1 cytochrome P450 family 7 subfamily A member 1 increases metabolic processing EXP CYP7A1 protein results in increased metabolism of 24-hydroxycholesterol CTD PMID:11013305 NCBI chr 4:74,343,101...74,372,628
Ensembl chr 4:74,342,856...74,372,638
JBrowse link
G LIPG lipase G, endothelial type decreases expression EXP 24-hydroxycholesterol results in decreased expression of LIPG mRNA; 24-hydroxycholesterol results in decreased expression of LIPG protein CTD PMID:15953354 NCBI chr 1:99,081,940...99,110,671
Ensembl chr 1:99,081,938...99,110,876
JBrowse link
G SCARB1 scavenger receptor class B member 1 affects localization EXP 24-hydroxycholesterol affects the localization of SCARB1 protein CTD PMID:16530456 NCBI chr14:28,301,421...28,393,568
Ensembl chr14:28,301,294...28,393,565
JBrowse link
(25R)-cholest-5-ene-3beta,26-diol term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CYP7A1 cytochrome P450 family 7 subfamily A member 1 increases metabolic processing EXP CYP7A1 protein results in increased metabolism of 27-hydroxycholesterol CTD PMID:10882719 NCBI chr 4:74,343,101...74,372,628
Ensembl chr 4:74,342,856...74,372,638
JBrowse link
1,10-phenanthroline term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ANPEP alanyl aminopeptidase, membrane multiple interactions
decreases activity
EXP Edetic Acid promotes the reaction [1,10-phenanthroline results in decreased activity of ANPEP protein] CTD PMID:17109655 NCBI chr 7:55,351,081...55,373,856
Ensembl chr 7:55,351,083...55,373,881
JBrowse link
G ENPEP glutamyl aminopeptidase multiple interactions EXP 1,10-phenanthroline inhibits the reaction [ENPEP protein results in increased hydrolysis of Aspartame] CTD PMID:8141778 NCBI chr 8:111,765,839...111,858,349
Ensembl chr 8:111,748,514...111,858,510
JBrowse link
1,3-thiazolidine-2,4-dione term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G IL6 interleukin 6 multiple interactions EXP 2,4-thiazolidinedione inhibits the reaction [Linoleic Acid results in increased expression of IL6 protein]; [Zinc co-treated with 2,4-thiazolidinedione] inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein results in increased expression of IL6 mRNA]] CTD PMID:14519784, PMID:15226458 NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,340...91,511,263
JBrowse link
G PPARG peroxisome proliferator activated receptor gamma multiple interactions EXP 2,4-thiazolidinedione binds to and results in increased activity of PPARG protein CTD PMID:14519784 NCBI chr13:68,301,566...68,433,951
Ensembl chr13:68,302,655...68,433,947
JBrowse link
G RELA RELA proto-oncogene, NF-kB subunit multiple interactions EXP 2,4-thiazolidinedione inhibits the reaction [Linoleic Acid results in increased activity of RELA protein] CTD PMID:14519784 NCBI chr 2:6,594,869...6,602,684
Ensembl chr 2:6,593,969...6,603,471
JBrowse link
G TNF tumor necrosis factor multiple interactions EXP [2,4-thiazolidinedione co-treated with Zinc] inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased activity of TNF protein]; [Zinc co-treated with 2,4-thiazolidinedione] inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein results in increased expression of IL6 mRNA]]; [Zinc co-treated with 2,4-thiazolidinedione] inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein results in increased expression of VCAM1 mRNA]] CTD PMID:15226458 NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,636...23,703,655
JBrowse link
G VCAM1 vascular cell adhesion molecule 1 multiple interactions EXP [Zinc co-treated with 2,4-thiazolidinedione] inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein results in increased expression of VCAM1 mRNA]] CTD PMID:15226458 NCBI chr 4:117,496,914...117,511,211
Ensembl chr 4:117,496,908...117,511,226
JBrowse link
17beta-estradiol term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ACACA acetyl-CoA carboxylase alpha increases phosphorylation EXP Estradiol results in increased phosphorylation of ACACA protein CTD PMID:15967841 NCBI chr12:38,580,916...38,875,067
Ensembl chr12:38,581,449...38,875,134
JBrowse link
G ADIPOQ adiponectin, C1Q and collagen domain containing multiple interactions
increases secretion
EXP Benzo(a)pyrene inhibits the reaction [ADIPOQ protein results in increased secretion of Estradiol]; bisphenol A promotes the reaction [ADIPOQ protein results in increased secretion of Estradiol]; Estradiol results in increased expression of and results in increased secretion of ADIPOQ protein; halowax 1051 inhibits the reaction [ADIPOQ protein results in increased secretion of Estradiol]; Hexachlorobenzene inhibits the reaction [ADIPOQ protein results in increased secretion of Estradiol] CTD PMID:28284726 NCBI chr13:124,633,906...124,646,237
Ensembl chr13:124,633,684...124,646,648
JBrowse link
G ADIPOR1 adiponectin receptor 1 increases expression EXP Estradiol results in increased expression of ADIPOR1 protein CTD PMID:28284726 NCBI chr10:24,907,491...24,923,540 JBrowse link
G ADIPOR2 adiponectin receptor 2 increases expression EXP Estradiol results in increased expression of ADIPOR2 protein CTD PMID:28284726 NCBI chr 5:68,755,789...68,807,247
Ensembl chr 5:68,755,811...68,807,235
JBrowse link
G AKT1 AKT serine/threonine kinase 1 increases phosphorylation EXP Estradiol results in increased phosphorylation of AKT1 protein CTD PMID:17348974
G CD40 CD40 molecule affects expression EXP Estradiol affects the expression of CD40 protein CTD PMID:15964915 NCBI chr17:48,286,116...48,298,188
Ensembl chr17:48,286,029...48,298,528
JBrowse link
G CD40LG CD40 ligand affects expression EXP Estradiol affects the expression of CD40LG protein CTD PMID:15964915 NCBI chr  X:111,778,666...111,788,901
Ensembl chr  X:111,778,493...111,789,711
JBrowse link
G ESR1 estrogen receptor 1 decreases expression
affects expression
EXP Estradiol results in decreased expression of ESR1 protein; Estradiol results in decreased expression of ESR1 protein alternative form
Estradiol affects the expression of ESR1 protein
CTD PMID:15653758, PMID:16431846, PMID:16680078, PMID:17348974 NCBI chr 1:14,217,032...14,604,906
Ensembl chr 1:14,217,036...14,493,363
JBrowse link
G ESR2 estrogen receptor 2 affects expression EXP Estradiol affects the expression of ESR2 protein CTD PMID:15653758, PMID:16680078 NCBI chr 1:193,823,666...193,907,330
Ensembl chr 1:193,722,164...193,906,565
JBrowse link
G F3 coagulation factor III, tissue factor affects expression EXP Estradiol affects the expression of F3 mRNA; Estradiol affects the expression of F3 protein CTD PMID:15964915 NCBI chr 4:122,827,018...122,837,673
Ensembl chr 4:122,826,992...122,837,672
JBrowse link
G FGF7 fibroblast growth factor 7 increases expression EXP Estradiol results in increased expression of FGF7 mRNA CTD PMID:15271478 NCBI chr 1:122,215,878...122,278,705
Ensembl chr 1:122,215,878...122,542,224
JBrowse link
G FSHB follicle stimulating hormone subunit beta multiple interactions
increases chemical synthesis
EXP [FSHB protein co-treated with IGF1 protein] results in increased abundance of Estradiol; deoxynivalenol affects the reaction [[FSHB protein co-treated with IGF1 protein] results in increased abundance of Estradiol]; lead acetate inhibits the reaction [FSHB protein results in increased chemical synthesis of Estradiol] CTD PMID:17656051, PMID:29273543 NCBI chr 2:30,395,769...30,399,282
Ensembl chr 2:30,395,018...30,399,274
JBrowse link
G HOXA10 homeobox A10 increases expression
multiple interactions
EXP Estradiol results in increased expression of HOXA10 mRNA
Estradiol promotes the reaction [Progesterone results in increased expression of HOXA10 mRNA]; Fulvestrant inhibits the reaction [Estradiol results in increased expression of HOXA10 mRNA]
CTD PMID:21705055 NCBI chr18:45,393,525...45,403,259
Ensembl chr18:45,393,712...45,403,257
JBrowse link
G IGF1 insulin like growth factor 1 multiple interactions
increases abundance
EXP [FSHB protein co-treated with IGF1 protein] results in increased abundance of Estradiol; deoxynivalenol affects the reaction [[FSHB protein co-treated with IGF1 protein] results in increased abundance of Estradiol]; deoxynivalenol affects the reaction [IGF1 protein results in increased abundance of Estradiol]; Zearalenone affects the reaction [IGF1 protein results in increased abundance of Estradiol] CTD PMID:17656051 NCBI chr 5:81,762,027...81,909,253
Ensembl chr 5:81,775,970...81,848,037
JBrowse link
G LEP leptin increases secretion
increases expression
EXP Estradiol results in increased secretion of LEP protein
Estradiol results in increased expression of LEP mRNA
CTD PMID:23153703 NCBI chr18:20,106,867...20,124,071
Ensembl chr18:20,106,868...20,123,447
JBrowse link
G LHB luteinizing hormone subunit beta multiple interactions
increases secretion
EXP Biological Products inhibits the reaction [LHB protein results in increased secretion of Estradiol]; Cod Liver Oil inhibits the reaction [LHB protein results in increased secretion of Estradiol]; Industrial Waste inhibits the reaction [LHB protein results in increased secretion of Estradiol] CTD PMID:26055946 NCBI chr 6:54,263,574...54,269,286 JBrowse link
G MMP2 matrix metallopeptidase 2 affects secretion EXP Estradiol affects the secretion of MMP2 protein CTD PMID:15653758 NCBI chr 6:30,059,247...30,087,031
Ensembl chr 6:30,058,594...30,086,982
JBrowse link
G NOS3 nitric oxide synthase 3 multiple interactions
affects expression
increases phosphorylation
decreases expression
EXP Estradiol results in increased phosphorylation of and results in increased activity of NOS3 protein; Fulvestrant inhibits the reaction [Estradiol results in increased phosphorylation of NOS3 protein]
Estradiol affects the expression of NOS3 mRNA
Estradiol results in decreased expression of NOS3 mRNA
CTD PMID:15653758, PMID:15967841, PMID:16680078, PMID:17618301 NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,156...6,228,938
JBrowse link
G PDGFB platelet derived growth factor subunit B multiple interactions EXP Estradiol affects the secretion of [PDGFB protein binds to PDGFB protein] CTD PMID:15653758 Ensembl chr 5:8,986,461...9,007,446 JBrowse link
G PGR progesterone receptor increases expression EXP Estradiol results in increased expression of PGR mRNA CTD PMID:16431846 NCBI chr 9:32,035,684...32,129,776
Ensembl chr 9:32,035,684...32,129,221
JBrowse link
G PRKAA1 protein kinase AMP-activated catalytic subunit alpha 1 multiple interactions EXP Estradiol results in increased phosphorylation of and results in increased activity of PRKAA1 protein CTD PMID:15967841 NCBI chr16:25,745,902...25,783,524
Ensembl chr16:25,745,321...25,783,610
JBrowse link
G PRLR prolactin receptor increases expression EXP Estradiol results in increased expression of PRLR protein alternative form CTD PMID:18492821 NCBI chr16:20,637,568...20,655,881
Ensembl chr16:20,618,875...20,810,140
JBrowse link
G PTGS2 prostaglandin-endoperoxide synthase 2 increases expression
multiple interactions
EXP Estradiol results in increased expression of PTGS2 mRNA
Fulvestrant inhibits the reaction [Estradiol results in increased expression of PTGS2 mRNA]
CTD PMID:21705055 NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,013...127,858,884
JBrowse link
G SPP1 secreted phosphoprotein 1 decreases expression EXP Estradiol results in decreased expression of SPP1 protein CTD PMID:15713688 NCBI chr 8:131,077,786...131,085,334
Ensembl chr 8:131,077,786...131,085,340
JBrowse link
G TNFRSF11B TNF receptor superfamily member 11b increases expression EXP Estradiol results in increased expression of TNFRSF11B protein CTD PMID:15713688 NCBI chr 4:19,850,212...19,879,132 JBrowse link
17beta-estradiol 3-benzoate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G FGF7 fibroblast growth factor 7 affects expression EXP estradiol 3-benzoate affects the expression of FGF7 mRNA CTD PMID:15976484 NCBI chr 1:122,215,878...122,278,705
Ensembl chr 1:122,215,878...122,542,224
JBrowse link
G FGFR2 fibroblast growth factor receptor 2 decreases expression
multiple interactions
EXP estradiol 3-benzoate results in decreased expression of FGFR2 mRNA alternative form
[Progesterone co-treated with estradiol 3-benzoate] results in decreased expression of FGFR2 mRNA alternative form
CTD PMID:15976484 NCBI chr14:131,183,095...131,285,001
Ensembl chr14:131,181,710...131,579,703
JBrowse link
2,2',4,4',5,5'-hexachlorobiphenyl term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CYP11A1 cytochrome P450, family 11, subfamily A, polypeptide 1 decreases activity EXP 2,4,5,2',4',5'-hexachlorobiphenyl results in decreased activity of CYP11A1 protein CTD PMID:16151981 NCBI chr 7:59,172,829...59,188,479
Ensembl chr 7:59,175,758...59,188,478
JBrowse link
G CYP19A2 cytochrome P450 19A2 multiple interactions
decreases activity
EXP [2,4,5,2',4',5'-hexachlorobiphenyl co-treated with Testosterone] affects the activity of CYP19A1 protein
2,4,5,2',4',5'-hexachlorobiphenyl results in decreased activity of CYP19A1 protein
CTD PMID:16151981 NCBI chr 1:120,652,172...120,695,899
Ensembl chr 1:120,367,667...120,695,899
JBrowse link
G HSD17B1 hydroxysteroid 17-beta dehydrogenase 1 multiple interactions
decreases activity
EXP [2,4,5,2',4',5'-hexachlorobiphenyl co-treated with Androstenedione] results in increased activity of HSD17B1 protein
2,4,5,2',4',5'-hexachlorobiphenyl results in decreased activity of HSD17B1 protein
CTD PMID:16151981 NCBI chr12:20,269,468...20,271,349
Ensembl chr12:20,269,056...20,279,569
JBrowse link
2,3-dimethoxynaphthalene-1,4-dione term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G HIF1A hypoxia inducible factor 1 subunit alpha multiple interactions EXP 2,3-dimethoxy-1,4-naphthoquinone inhibits the reaction [S-Nitrosoglutathione results in increased expression of HIF1A protein]; 2,3-dimethoxy-1,4-naphthoquinone inhibits the reaction [TNF protein results in increased expression of HIF1A protein] CTD PMID:11514583 NCBI chr 1:190,625,436...190,673,926
Ensembl chr 1:190,625,181...190,674,850
JBrowse link
G TNF tumor necrosis factor multiple interactions EXP 2,3-dimethoxy-1,4-naphthoquinone inhibits the reaction [TNF protein results in increased expression of HIF1A protein] CTD PMID:11514583 NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,636...23,703,655
JBrowse link
G TPO thyroid peroxidase decreases activity EXP 2,3-dimethoxy-1,4-naphthoquinone results in decreased activity of TPO protein CTD PMID:11815678 NCBI chr 3:132,384,677...132,409,750
Ensembl chr 3:132,384,583...132,408,943
JBrowse link
20-hydroxycholesterol term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CYP7A1 cytochrome P450 family 7 subfamily A member 1 increases metabolic processing EXP CYP7A1 protein results in increased metabolism of 20-hydroxycholesterol CTD PMID:10882719 NCBI chr 4:74,343,101...74,372,628
Ensembl chr 4:74,342,856...74,372,638
JBrowse link
25-hydroxycholesterol term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CYP7A1 cytochrome P450 family 7 subfamily A member 1 increases metabolic processing EXP CYP7A1 protein results in increased metabolism of 25-hydroxycholesterol CTD PMID:10882719 NCBI chr 4:74,343,101...74,372,628
Ensembl chr 4:74,342,856...74,372,638
JBrowse link
26-hydroxycholesterol term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CYP7A1 cytochrome P450 family 7 subfamily A member 1 increases metabolic processing EXP CYP7A1 protein results in increased metabolism of 27-hydroxycholesterol CTD PMID:10882719 NCBI chr 4:74,343,101...74,372,628
Ensembl chr 4:74,342,856...74,372,638
JBrowse link
3',5'-cyclic GMP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G PDE5A phosphodiesterase 5A increases degradation EXP PDE5 protein results in increased degradation of Cyclic GMP CTD PMID:18669600 NCBI chr 8:104,270,858...104,420,955
Ensembl chr 8:104,270,881...104,420,947
JBrowse link
G PDE6C phosphodiesterase 6C increases degradation EXP PDE6C protein results in increased degradation of Cyclic GMP CTD PMID:18669600 NCBI chr14:105,010,974...105,122,628
Ensembl chr14:105,011,922...105,037,498
Ensembl chr14:105,011,922...105,037,498
JBrowse link
G PRKG1 protein kinase cGMP-dependent 1 increases activity EXP Cyclic GMP results in increased activity of PRKG1 protein CTD PMID:18037907 NCBI chr14:97,558,531...98,793,080
Ensembl chr14:97,560,785...98,793,318
JBrowse link
3,3',4,4',5-pentachlorobiphenyl term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G AHR aryl hydrocarbon receptor increases expression
multiple interactions
increases activity
EXP 3,4,5,3',4'-pentachlorobiphenyl results in increased expression of AHR protein
epigallocatechin gallate inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of AHR protein]
CTD PMID:16552988, PMID:22521609 NCBI chr 9:86,511,866...86,555,950
Ensembl chr 9:86,511,369...86,555,943
JBrowse link
G CAV1 caveolin 1 multiple interactions EXP CAV1 mutant form inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CCL2 mRNA]; CAV1 mutant form inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VCAM1 mRNA]; CAV1 mutant form inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VCAM1 protein]; CAV1 mutant form promotes the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of NQO1 mRNA] CTD PMID:19265715, PMID:20406653, PMID:24709675 NCBI chr18:29,648,120...29,682,451
Ensembl chr18:29,649,992...29,682,465
JBrowse link
G CCL2 chemokine (C-C motif) ligand 2 increases expression
multiple interactions
EXP 3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CCL2 mRNA; 3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CCL2 protein
CAV1 mutant form inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CCL2 mRNA]; epigallocatechin gallate inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CCL2 mRNA]; epigallocatechin gallate inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CCL2 protein]; NFE2L2 protein affects the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CCL2 mRNA]
CTD PMID:19265715, PMID:22521609 NCBI chr12:40,798,109...40,800,013
Ensembl chr12:40,798,109...40,800,028
JBrowse link
G CTSB cathepsin B decreases expression EXP 3,4,5,3',4'-pentachlorobiphenyl results in decreased expression of CTSB mRNA CTD PMID:16291828 NCBI chr14:15,014,139...15,035,081
Ensembl chr14:15,011,711...15,034,737
JBrowse link
G CYP11A1 cytochrome P450, family 11, subfamily A, polypeptide 1 decreases activity EXP 3,4,5,3',4'-pentachlorobiphenyl results in decreased activity of CYP11A1 protein CTD PMID:16151981 NCBI chr 7:59,172,829...59,188,479
Ensembl chr 7:59,175,758...59,188,478
JBrowse link
G CYP19A2 cytochrome P450 19A2 increases activity
multiple interactions
EXP 3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP19A1 protein
[3,4,5,3',4'-pentachlorobiphenyl co-treated with Testosterone] results in increased activity of CYP19A1 protein
CTD PMID:16151981 NCBI chr 1:120,652,172...120,695,899
Ensembl chr 1:120,367,667...120,695,899
JBrowse link
G CYP1A1 cytochrome P450 1A1 multiple interactions
increases expression
EXP epigallocatechin gallate inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CYP1A1 mRNA]; epigallocatechin gallate inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CYP1A1 protein]; NFE2L2 protein affects the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CYP1A1 mRNA]; Quercetin inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CYP1A1 protein]
3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CYP1A1 mRNA; 3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CYP1A1 protein
CTD PMID:16291828, PMID:19608276, PMID:22521609 NCBI chr 7:58,802,887...58,809,155
Ensembl chr 7:58,780,105...58,809,755
JBrowse link
G GSTO1 glutathione S-transferase omega 1 multiple interactions EXP [epigallocatechin gallate co-treated with 3,4,5,3',4'-pentachlorobiphenyl] results in increased expression of GSTO1 mRNA CTD PMID:22521609 NCBI chr14:115,206,434...115,216,624
Ensembl chr14:115,206,188...115,216,613
JBrowse link
G HSD17B1 hydroxysteroid 17-beta dehydrogenase 1 decreases activity EXP 3,4,5,3',4'-pentachlorobiphenyl results in decreased activity of HSD17B1 protein CTD PMID:16151981 NCBI chr12:20,269,468...20,271,349
Ensembl chr12:20,269,056...20,279,569
JBrowse link
G MAPK1 mitogen-activated protein kinase 1 multiple interactions EXP 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 3,4,5,3',4'-pentachlorobiphenyl results in increased phosphorylation of and results in increased activity of MAPK1 protein CTD PMID:20406653 NCBI chr14:50,083,079...50,165,528
Ensembl chr14:50,082,896...50,165,523
JBrowse link
G MAPK3 mitogen-activated protein kinase 3 multiple interactions EXP 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 3,4,5,3',4'-pentachlorobiphenyl results in increased phosphorylation of and results in increased activity of MAPK3 protein CTD PMID:20406653 NCBI chr 3:18,291,444...18,299,410
Ensembl chr 3:18,291,445...18,299,567
JBrowse link
G NFE2L2 nuclear factor, erythroid 2 like 2 multiple interactions EXP NFE2L2 protein affects the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CCL2 mRNA]; NFE2L2 protein affects the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CYP1A1 mRNA]; NFE2L2 protein affects the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VCAM1 mRNA] CTD PMID:22521609 NCBI chr15:82,967,485...83,146,185
Ensembl chr15:82,973,648...83,146,183
JBrowse link
G NQO1 NAD(P)H quinone dehydrogenase 1 increases expression
multiple interactions
EXP 3,4,5,3',4'-pentachlorobiphenyl results in increased expression of NQO1 mRNA
[epigallocatechin gallate co-treated with 3,4,5,3',4'-pentachlorobiphenyl] results in increased expression of NQO1 mRNA; CAV1 mutant form promotes the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of NQO1 mRNA]
CTD PMID:22521609, PMID:24709675 NCBI chr 6:17,292,962...17,302,593
Ensembl chr 6:17,292,769...17,302,590
JBrowse link
G SLC5A5 solute carrier family 5 member 5 decreases expression EXP 3,4,5,3',4'-pentachlorobiphenyl results in decreased expression of SLC5A5 mRNA CTD PMID:16291828 NCBI chr 2:59,869,157...59,885,086
Ensembl chr 2:59,869,154...59,885,265
JBrowse link
G VCAM1 vascular cell adhesion molecule 1 multiple interactions
increases expression
EXP 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VCAM1 mRNA]; CAV1 mutant form inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VCAM1 mRNA]; CAV1 mutant form inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VCAM1 protein]; epigallocatechin gallate inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VCAM1 mRNA]; epigallocatechin gallate inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VCAM1 protein]; NFE2L2 protein affects the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VCAM1 mRNA]
3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VCAM1 mRNA; 3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VCAM1 protein
CTD PMID:20406653, PMID:22521609, PMID:24709675 NCBI chr 4:117,496,914...117,511,211
Ensembl chr 4:117,496,908...117,511,226
JBrowse link
3,3',4,4'-tetrachlorobiphenyl term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G AHR aryl hydrocarbon receptor multiple interactions EXP 3,4,3',4'-tetrachlorobiphenyl affects the localization of and results in increased activity of AHR protein; [alpha-naphthoflavone co-treated with 3,4,3',4'-tetrachlorobiphenyl] results in increased activity of AHR protein; epigallocatechin gallate inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl affects the localization of and results in increased activity of AHR protein]; epigallocatechin gallate inhibits the reaction [[alpha-naphthoflavone co-treated with 3,4,3',4'-tetrachlorobiphenyl] results in increased activity of AHR protein]; Quercetin inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl affects the localization of and results in increased activity of AHR protein] CTD PMID:12970578 NCBI chr 9:86,511,866...86,555,950
Ensembl chr 9:86,511,369...86,555,943
JBrowse link
G CAV1 caveolin 1 multiple interactions EXP 3,4,3',4'-tetrachlorobiphenyl results in increased expression of and results in increased phosphorylation of CAV1 protein; CAV1 mutant form inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of VCAM1 protein]; Quercetin inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of and results in increased phosphorylation of CAV1 protein] CTD PMID:19608276, PMID:20406653 NCBI chr18:29,648,120...29,682,451
Ensembl chr18:29,649,992...29,682,465
JBrowse link
G CCL2 chemokine (C-C motif) ligand 2 increases secretion
increases expression
multiple interactions
EXP 3,4,3',4'-tetrachlorobiphenyl results in increased secretion of CCL2 protein
3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 mRNA
[2,2'-azobis(2-amidinopropane) results in increased oxidation of Docosahexaenoic Acids] inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 mRNA]; [2,2'-azobis(2-amidinopropane) results in increased oxidation of Docosahexaenoic Acids] inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 protein]; [2,2'-azobis(2-amidinopropane) results in increased oxidation of Eicosapentaenoic Acid] inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 mRNA]; [2,2'-azobis(2-amidinopropane) results in increased oxidation of Eicosapentaenoic Acid] inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 protein]; Acetylcysteine inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 mRNA]; alpha-naphthoflavone inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 mRNA]; pyrazolanthrone inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 mRNA]; SB 203580 inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 mRNA]; sodium borohydride inhibits the reaction [[2,2'-azobis(2-amidinopropane) results in increased oxidation of Docosahexaenoic Acids] inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 mRNA]]; sulforafan inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 mRNA]; Tretinoin promotes the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 protein]
CTD PMID:19265715, PMID:21130106 NCBI chr12:40,798,109...40,800,013
Ensembl chr12:40,798,109...40,800,028
JBrowse link
G CYP1A1 cytochrome P450 1A1 increases activity
increases expression
multiple interactions
EXP 3,4,3',4'-tetrachlorobiphenyl results in increased activity of CYP1A1 protein
3,4,3',4'-tetrachlorobiphenyl results in increased expression of CYP1A1 mRNA; 3,4,3',4'-tetrachlorobiphenyl results in increased expression of CYP1A1 protein
alpha-naphthoflavone inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased activity of CYP1A1 protein]; alpha-naphthoflavone inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CYP1A1 mRNA]; epigallocatechin gallate inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased activity of CYP1A1 protein]; epigallocatechin gallate inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CYP1A1 mRNA]; Quercetin inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased activity of CYP1A1 protein]; Quercetin inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CYP1A1 mRNA]; Quercetin inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CYP1A1 protein]
CTD PMID:12970578, PMID:19608276 NCBI chr 7:58,802,887...58,809,155
Ensembl chr 7:58,780,105...58,809,755
JBrowse link
G MAPK1 mitogen-activated protein kinase 1 multiple interactions
increases phosphorylation
EXP 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased phosphorylation of MAPK1 protein] CTD PMID:20406653 NCBI chr14:50,083,079...50,165,528
Ensembl chr14:50,082,896...50,165,523
JBrowse link
G MAPK3 mitogen-activated protein kinase 3 multiple interactions
increases phosphorylation
EXP 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased phosphorylation of MAPK3 protein] CTD PMID:20406653 NCBI chr 3:18,291,444...18,299,410
Ensembl chr 3:18,291,445...18,299,567
JBrowse link
G RELA RELA proto-oncogene, NF-kB subunit increases activity
multiple interactions
EXP 3,4,3',4'-tetrachlorobiphenyl results in increased activity of RELA protein
[2,2'-azobis(2-amidinopropane) results in increased oxidation of Docosahexaenoic Acids] inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased activity of RELA protein]
CTD PMID:21130106 NCBI chr 2:6,594,869...6,602,684
Ensembl chr 2:6,593,969...6,603,471
JBrowse link
G SELE selectin E increases expression
multiple interactions
EXP 3,4,3',4'-tetrachlorobiphenyl results in increased expression of SELE mRNA
Quercetin inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of SELE mRNA]
CTD PMID:19608276 NCBI chr 4:81,289,061...81,299,657 JBrowse link
G SELP selectin P multiple interactions
increases expression
EXP Quercetin inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of SELP mRNA] CTD PMID:19608276 NCBI chr 4:81,376,804...81,401,240
Ensembl chr 4:81,365,740...81,406,203
JBrowse link
G VCAM1 vascular cell adhesion molecule 1 multiple interactions
increases expression
EXP 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of VCAM1 mRNA]; CAV1 mutant form inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of VCAM1 protein]; Quercetin inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of VCAM1 mRNA]
3,4,3',4'-tetrachlorobiphenyl results in increased expression of VCAM1 mRNA; 3,4,3',4'-tetrachlorobiphenyl results in increased expression of VCAM1 protein
CTD PMID:19608276, PMID:20406653 NCBI chr 4:117,496,914...117,511,211
Ensembl chr 4:117,496,908...117,511,226
JBrowse link
3-methyladenine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G BAX BCL2 associated X, apoptosis regulator multiple interactions EXP 3-methyladenine inhibits the reaction [Zinc Sulfate results in increased expression of BAX mRNA] CTD PMID:28803810 NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,187,260...54,228,144
JBrowse link
G BECN1 beclin 1 multiple interactions EXP 3-methyladenine inhibits the reaction [Zinc Sulfate results in increased expression of BECN1 protein] CTD PMID:28803810 NCBI chr12:20,041,914...20,054,249
Ensembl chr12:20,041,956...20,054,373
JBrowse link
G CASP3 caspase 3 multiple interactions EXP 3-methyladenine inhibits the reaction [Zinc Sulfate results in increased cleavage of CASP3 protein]; 3-methyladenine promotes the reaction [ochratoxin A results in increased cleavage of CASP3 protein] CTD PMID:28803810, PMID:30287338 NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,749...45,763,773
JBrowse link
G CASP8 caspase 8 multiple interactions EXP 3-methyladenine inhibits the reaction [Zinc Sulfate results in increased cleavage of CASP8 protein] CTD PMID:28803810 NCBI chr15:104,923,659...104,948,470
Ensembl chr15:104,923,953...104,948,470
JBrowse link
G CYCS cytochrome c, somatic multiple interactions EXP 3-methyladenine inhibits the reaction [Zinc Sulfate results in increased expression of CYCS mRNA] CTD PMID:28803810 NCBI chr18:47,169,921...47,172,212
Ensembl chr18:47,169,866...47,173,866
JBrowse link
G PARP1 poly(ADP-ribose) polymerase 1 multiple interactions EXP 3-methyladenine promotes the reaction [ochratoxin A results in increased cleavage of PARP1 protein] CTD PMID:30287338 NCBI chr10:14,203,157...14,241,164
Ensembl chr10:14,203,159...14,241,197
JBrowse link
G SQSTM1 sequestosome 1 multiple interactions EXP 3-methyladenine inhibits the reaction [Zinc Sulfate results in decreased expression of SQSTM1 protein] CTD PMID:28803810 NCBI chr 2:78,752,768...78,763,998
Ensembl chr 2:78,752,768...78,784,256
JBrowse link
4,4'-diisothiocyano-trans-stilbene-2,2'-disulfonic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G SLC4A2 solute carrier family 4 member 2 multiple interactions EXP 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid promotes the reaction [SLC4A2 protein binds to SLC4A2 protein] CTD PMID:10387099 NCBI chr18:6,149,459...6,166,622
Ensembl chr18:6,149,458...6,165,212
JBrowse link
5-methyl-pyrazole-3-carboxylic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G DAO D-amino acid oxidase decreases activity EXP 5-methylpyrazole-3-carboxylic acid results in decreased activity of DAO protein CTD PMID:20952482 NCBI chr14:41,931,549...41,950,628
Ensembl chr14:41,929,215...41,950,633
JBrowse link
6beta-hydroxytestosterone term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CYP3A29 cytochrome P450 3A29 increases chemical synthesis
multiple interactions
EXP CYP3A29 protein results in increased chemical synthesis of 6 beta-hydroxytestosterone
Ketoconazole inhibits the reaction [CYP3A29 protein results in increased chemical synthesis of 6 beta-hydroxytestosterone]; Troleandomycin inhibits the reaction [CYP3A29 protein results in increased chemical synthesis of 6 beta-hydroxytestosterone]
CTD PMID:20863320 NCBI chr 3:6,738,502...6,778,121 JBrowse link
7,12-dimethyltetraphene term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CYP1A1 cytochrome P450 1A1 multiple interactions EXP 7-ketocholesterol inhibits the reaction [[Benzo(a)pyrene co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of CYP1A1 protein]; [Benzo(a)pyrene co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of CYP1A1 protein CTD PMID:11042205 NCBI chr 7:58,802,887...58,809,155
Ensembl chr 7:58,780,105...58,809,755
JBrowse link
7-ketocholesterol term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CYP1A1 cytochrome P450 1A1 multiple interactions EXP 7-ketocholesterol inhibits the reaction [[Benzo(a)pyrene co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of CYP1A1 protein] CTD PMID:11042205 NCBI chr 7:58,802,887...58,809,155
Ensembl chr 7:58,780,105...58,809,755
JBrowse link
adenosine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G MYL9 myosin light chain 9 decreases phosphorylation
multiple interactions
EXP Adenosine results in decreased phosphorylation of MYL9 protein
8-phenyltheophylline inhibits the reaction [Adenosine results in decreased phosphorylation of MYL9 protein]
CTD PMID:10942722 NCBI chr17:39,788,165...39,795,240
Ensembl chr17:39,788,199...39,795,296
JBrowse link
aldosterone term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G AGT angiotensinogen multiple interactions
increases secretion
EXP 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer inhibits the reaction [AGT protein results in increased secretion of Aldosterone]; Enkephalin, D-Penicillamine (2,5)- inhibits the reaction [AGT protein results in increased secretion of Aldosterone] CTD PMID:22100847 NCBI chr14:59,643,030...59,656,835
Ensembl chr14:59,643,292...59,672,428
JBrowse link
G ATP1A1 ATPase Na+/K+ transporting subunit alpha 1 increases expression EXP Aldosterone results in increased expression of ATP1A1 protein CTD PMID:28438630 NCBI chr 4:104,353,506...104,384,321
Ensembl chr 4:104,353,506...104,384,606
JBrowse link
G GCLC glutamate-cysteine ligase catalytic subunit increases expression EXP Aldosterone results in increased expression of GCLC protein CTD PMID:24512358 NCBI chr 7:27,209,565...27,253,535
Ensembl chr 7:27,209,564...27,253,535
JBrowse link
G HMOX1 heme oxygenase 1 increases expression EXP Aldosterone results in increased expression of HMOX1 protein CTD PMID:24512358
G NFE2L2 nuclear factor, erythroid 2 like 2 multiple interactions EXP 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Aldosterone results in increased activity of NFE2L2 protein]; 3-benzyl-7-(2-benzoxazolyl)thio-1,2,3-triazolo(4,5-d)pyrimidine inhibits the reaction [Aldosterone results in increased activity of NFE2L2 protein]; acetovanillone inhibits the reaction [Aldosterone results in increased activity of NFE2L2 protein]; Acetylcysteine inhibits the reaction [Aldosterone results in increased activity of NFE2L2 protein]; Aldosterone results in increased expression of and results in increased activity of NFE2L2 protein; diphenyleneiodonium inhibits the reaction [Aldosterone results in increased activity of NFE2L2 protein]; Eplerenone inhibits the reaction [Aldosterone results in increased activity of NFE2L2 protein]; Ro 32-0432 inhibits the reaction [Aldosterone results in increased activity of NFE2L2 protein]; tempol inhibits the reaction [Aldosterone results in increased activity of NFE2L2 protein]; Thioctic Acid inhibits the reaction [Aldosterone results in increased activity of NFE2L2 protein]; W 7 inhibits the reaction [Aldosterone results in increased activity of NFE2L2 protein] CTD PMID:24512358 NCBI chr15:82,967,485...83,146,185
Ensembl chr15:82,973,648...83,146,183
JBrowse link
G SOD1 superoxide dismutase 1 increases expression EXP Aldosterone results in increased expression of SOD1 protein CTD PMID:24512358 NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,749
JBrowse link
G TXNRD1 thioredoxin reductase 1 increases expression EXP Aldosterone results in increased expression of TXNRD1 protein CTD PMID:24512358 NCBI chr 5:80,170,334...80,213,889
Ensembl chr 5:80,168,523...80,288,075
JBrowse link
all-trans-retinoic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CCL2 chemokine (C-C motif) ligand 2 multiple interactions EXP Tretinoin promotes the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 protein] CTD PMID:21130106 NCBI chr12:40,798,109...40,800,013
Ensembl chr12:40,798,109...40,800,028
JBrowse link
G GPD1 glycerol-3-phosphate dehydrogenase 1 decreases activity EXP Tretinoin results in decreased activity of GPD1 protein CTD PMID:15583048 NCBI chr 5:16,008,179...16,021,676
Ensembl chr 5:16,007,448...16,017,825
JBrowse link
G NRL neural retina leucine zipper increases expression EXP Tretinoin results in increased expression of NRL protein CTD PMID:16854989 NCBI chr 7:75,199,048...75,211,655
Ensembl chr 7:75,199,196...75,210,529
JBrowse link
all-trans-retinyl palmitate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G PDIA3 protein disulfide isomerase family A member 3 increases hydrolysis EXP PDIA3 protein results in increased hydrolysis of retinol palmitate CTD PMID:16798117 NCBI chr 1:127,786,174...127,814,096
Ensembl chr 1:127,785,772...127,814,196
JBrowse link
androst-4-ene-3,17-dione term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G HSD17B1 hydroxysteroid 17-beta dehydrogenase 1 multiple interactions EXP [2,4,5,2',4',5'-hexachlorobiphenyl co-treated with Androstenedione] results in increased activity of HSD17B1 protein CTD PMID:16151981 NCBI chr12:20,269,468...20,271,349
Ensembl chr12:20,269,056...20,279,569
JBrowse link
G INS insulin multiple interactions EXP 9-deoxy-delta-9-prostaglandin D2 inhibits the reaction [[LHB protein co-treated with INS protein] results in increased abundance of Androstenedione]; [LHB protein co-treated with INS protein] results in increased abundance of Androstenedione; Troglitazone inhibits the reaction [[LHB protein co-treated with INS protein] results in increased abundance of Androstenedione] CTD PMID:11889176 NCBI chr 2:1,496,842...1,498,052
Ensembl chr 2:1,496,842...1,497,841
JBrowse link
G LHB luteinizing hormone subunit beta multiple interactions EXP 9-deoxy-delta-9-prostaglandin D2 inhibits the reaction [[LHB protein co-treated with INS protein] results in increased abundance of Androstenedione]; [LHB protein co-treated with INS protein] results in increased abundance of Androstenedione; Troglitazone inhibits the reaction [[LHB protein co-treated with INS protein] results in increased abundance of Androstenedione] CTD PMID:11889176 NCBI chr 6:54,263,574...54,269,286 JBrowse link
arotinoid acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G FABP4 fatty acid binding protein 4, adipocyte decreases expression EXP 4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid results in decreased expression of FABP4 mRNA CTD PMID:15583048 NCBI chr 4:55,096,400...55,101,209
Ensembl chr 4:55,096,404...55,101,897
JBrowse link
G GPD1 glycerol-3-phosphate dehydrogenase 1 decreases activity EXP 4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid results in decreased activity of GPD1 protein CTD PMID:15583048 NCBI chr 5:16,008,179...16,021,676
Ensembl chr 5:16,007,448...16,017,825
JBrowse link
G NR2F1 nuclear receptor subfamily 2 group F member 1 increases expression EXP 4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid results in increased expression of NR2F1 mRNA CTD PMID:15583048 NCBI chr 2:100,447,661...100,457,510
Ensembl chr 2:100,447,847...100,457,904
JBrowse link
G PPARG peroxisome proliferator activated receptor gamma decreases expression EXP 4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid results in decreased expression of PPARG mRNA CTD PMID:15583048 NCBI chr13:68,301,566...68,433,951
Ensembl chr13:68,302,655...68,433,947
JBrowse link
G RXRA retinoid X receptor alpha decreases expression EXP 4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid results in decreased expression of RXRA mRNA CTD PMID:15583048 NCBI chr 1:273,698,842...273,797,622
Ensembl chr 1:273,705,503...273,797,622
JBrowse link
G SREBP-1 sterol regulatory element binding protein 1 decreases expression EXP 4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid results in decreased expression of SREBP-1 mRNA CTD PMID:15583048
aspartame term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ENPEP glutamyl aminopeptidase multiple interactions
increases hydrolysis
EXP 1,10-phenanthroline inhibits the reaction [ENPEP protein results in increased hydrolysis of Aspartame]; amastatin inhibits the reaction [ENPEP protein results in increased hydrolysis of Aspartame]; Calcium Chloride promotes the reaction [ENPEP protein results in increased hydrolysis of Aspartame] CTD PMID:8141778 NCBI chr 8:111,765,839...111,858,349
Ensembl chr 8:111,748,514...111,858,510
JBrowse link
ATP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G BCL2 BCL2 apoptosis regulator multiple interactions
increases expression
EXP tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [Adenosine Triphosphate results in increased expression of BCL2 protein] CTD PMID:17997382 NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,288,544...158,518,879
JBrowse link
G CASP8 caspase 8 increases activity
multiple interactions
EXP Adenosine Triphosphate results in increased activity of CASP8 protein
tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [Adenosine Triphosphate results in increased activity of CASP8 protein]
CTD PMID:17997382 NCBI chr15:104,923,659...104,948,470
Ensembl chr15:104,923,953...104,948,470
JBrowse link
G CYCS cytochrome c, somatic affects localization
multiple interactions
EXP Adenosine Triphosphate affects the localization of CYCS protein
[Calcium co-treated with Phosphates co-treated with Adenosine Triphosphate] affects the localization of CYCS protein; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [Adenosine Triphosphate affects the localization of CYCS protein]
CTD PMID:16489745, PMID:17997382 NCBI chr18:47,169,921...47,172,212
Ensembl chr18:47,169,866...47,173,866
JBrowse link
G MYL9 myosin light chain 9 decreases phosphorylation
multiple interactions
EXP Adenosine Triphosphate results in decreased phosphorylation of MYL9 protein
1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [Adenosine Triphosphate promotes the reaction [calyculin A results in increased phosphorylation of MYL9 protein]]; Adenosine Triphosphate promotes the reaction [calyculin A results in increased phosphorylation of MYL9 protein]
CTD PMID:10942722 NCBI chr17:39,788,165...39,795,240
Ensembl chr17:39,788,199...39,795,296
JBrowse link
G TNF tumor necrosis factor increases expression
multiple interactions
EXP Adenosine Triphosphate results in increased expression of TNF protein
tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [Adenosine Triphosphate results in increased expression of TNF protein]
CTD PMID:17997382 NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,636...23,703,655
JBrowse link
benzo[a]pyrene term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ADIPOQ adiponectin, C1Q and collagen domain containing multiple interactions EXP Benzo(a)pyrene inhibits the reaction [ADIPOQ protein results in increased expression of CYP19A1 protein]; Benzo(a)pyrene inhibits the reaction [ADIPOQ protein results in increased secretion of Estradiol]; Benzo(a)pyrene results in decreased expression of and results in decreased secretion of ADIPOQ protein CTD PMID:28284726 NCBI chr13:124,633,906...124,646,237
Ensembl chr13:124,633,684...124,646,648
JBrowse link
G ADIPOR1 adiponectin receptor 1 decreases expression EXP Benzo(a)pyrene results in decreased expression of ADIPOR1 protein CTD PMID:28284726 NCBI chr10:24,907,491...24,923,540 JBrowse link
G ADIPOR2 adiponectin receptor 2 decreases expression EXP Benzo(a)pyrene results in decreased expression of ADIPOR2 protein CTD PMID:28284726 NCBI chr 5:68,755,789...68,807,247
Ensembl chr 5:68,755,811...68,807,235
JBrowse link
G CYP19A2 cytochrome P450 19A2 multiple interactions EXP Benzo(a)pyrene inhibits the reaction [ADIPOQ protein results in increased expression of CYP19A1 protein] CTD PMID:28284726 NCBI chr 1:120,652,172...120,695,899
Ensembl chr 1:120,367,667...120,695,899
JBrowse link
G CYP1A1 cytochrome P450 1A1 increases expression
multiple interactions
EXP Benzo(a)pyrene results in increased expression of CYP1A1 protein
7-ketocholesterol inhibits the reaction [[Benzo(a)pyrene co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of CYP1A1 protein]; [Benzo(a)pyrene co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of CYP1A1 protein
CTD PMID:11042205, PMID:18636242 NCBI chr 7:58,802,887...58,809,155
Ensembl chr 7:58,780,105...58,809,755
JBrowse link
betamethasone term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G HMOX2 heme oxygenase 2 increases expression EXP Betamethasone results in increased expression of HMOX2 protein CTD PMID:11698254 NCBI chr 3:37,829,044...37,868,163
Ensembl chr 3:37,831,434...37,868,128
JBrowse link
G PTGS2 prostaglandin-endoperoxide synthase 2 decreases expression EXP Betamethasone results in decreased expression of PTGS2 protein CTD PMID:11698254 NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,013...127,858,884
JBrowse link
brimonidine tartrate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CREB1 cAMP responsive element binding protein 1 increases phosphorylation
multiple interactions
EXP Brimonidine Tartrate results in increased phosphorylation of CREB1 protein
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Brimonidine Tartrate results in increased phosphorylation of CREB1 protein]
CTD PMID:17680988 NCBI chr15:110,705,548...110,773,037
Ensembl chr15:110,697,408...110,771,755
JBrowse link
caffeine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G RYR1 ryanodine receptor 1 increases activity
multiple interactions
EXP Caffeine results in increased activity of RYR1 protein; Caffeine results in increased activity of RYR1 protein mutant form
Caffeine promotes the reaction [Ryanodine binds to RYR1 protein mutant form]; Caffeine promotes the reaction [Ryanodine binds to RYR1 protein]; Dantrolene inhibits the reaction [Caffeine promotes the reaction [Ryanodine binds to RYR1 protein mutant form]]; Dantrolene inhibits the reaction [Caffeine promotes the reaction [Ryanodine binds to RYR1 protein]]; Dantrolene inhibits the reaction [Caffeine results in increased activity of RYR1 protein mutant form]; Dantrolene inhibits the reaction [Caffeine results in increased activity of RYR1 protein]
CTD PMID:11278295 NCBI chr 6:47,339,759...47,458,457 JBrowse link
calyculin a term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G MYL9 myosin light chain 9 multiple interactions
increases phosphorylation
EXP 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [Adenosine Triphosphate promotes the reaction [calyculin A results in increased phosphorylation of MYL9 protein]]; Adenosine Triphosphate promotes the reaction [calyculin A results in increased phosphorylation of MYL9 protein] CTD PMID:10942722 NCBI chr17:39,788,165...39,795,240
Ensembl chr17:39,788,199...39,795,296
JBrowse link
carvacrol term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G RYR1 ryanodine receptor 1 increases activity EXP carvacrol results in increased activity of RYR1 protein CTD PMID:17641978 NCBI chr 6:47,339,759...47,458,457 JBrowse link
chenodeoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ACHE acetylcholinesterase increases activity EXP Chenodeoxycholic Acid results in increased activity of ACHE protein CTD PMID:3697337 NCBI chr 3:8,732,451...8,738,274
Ensembl chr 3:8,732,324...8,739,149
JBrowse link
G LRP2 LDL receptor related protein 2 increases expression EXP Chenodeoxycholic Acid results in increased expression of LRP2 protein CTD PMID:15375181 NCBI chr15:75,565,299...75,754,604
Ensembl chr15:75,565,301...75,716,694
JBrowse link
chlortetracycline term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G SLCO1A2 solute carrier organic anion transporter family member 1A2 multiple interactions
increases uptake
EXP Chlortetracycline inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; daidzein inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline]; epigallocatechin gallate inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline]; Genistein inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline]; naringin inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline]; Oxytetracycline inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline] CTD PMID:31287969 NCBI chr 5:52,020,303...52,133,132
Ensembl chr 5:52,037,218...52,131,789
JBrowse link
cholesterol term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G APOA1 apolipoprotein A1 increases transport
multiple interactions
EXP APOA1 protein results in increased transport of Cholesterol
24-hydroxycholesterol promotes the reaction [APOA1 protein results in increased transport of Cholesterol]; Fenofibrate inhibits the reaction [APOA1 protein results in increased transport of Cholesterol]; Fenofibrate promotes the reaction [APOA1 protein results in increased transport of Cholesterol]; Pioglitazone promotes the reaction [APOA1 protein results in increased transport of Cholesterol]; TO-901317 promotes the reaction [APOA1 protein results in increased transport of Cholesterol]; Troglitazone promotes the reaction [APOA1 protein results in increased transport of Cholesterol]
CTD PMID:16530456 NCBI chr 9:44,216,481...44,218,360
Ensembl chr 9:44,216,393...44,218,978
JBrowse link
cholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ACHE acetylcholinesterase increases activity EXP Cholic Acid results in increased activity of ACHE protein CTD PMID:3697337 NCBI chr 3:8,732,451...8,738,274
Ensembl chr 3:8,732,324...8,739,149
JBrowse link
G LRP2 LDL receptor related protein 2 increases expression EXP Cholic Acid results in increased expression of LRP2 protein CTD PMID:15375181 NCBI chr15:75,565,299...75,754,604
Ensembl chr15:75,565,301...75,716,694
JBrowse link
cortisol term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G AGT angiotensinogen multiple interactions
increases secretion
EXP D-Ala(2),MePhe(4),Met(0)-ol-enkephalin promotes the reaction [AGT protein results in increased secretion of Hydrocortisone] CTD PMID:22100847 NCBI chr14:59,643,030...59,656,835
Ensembl chr14:59,643,292...59,672,428
JBrowse link
G POMC proopiomelanocortin multiple interactions
increases abundance
increases secretion
EXP Ditiocarb promotes the reaction [Sodium Selenite inhibits the reaction [POMC protein results in increased secretion of Hydrocortisone]]; Sodium Selenite inhibits the reaction [POMC protein results in increased secretion of Hydrocortisone]
POMC protein alternative form results in increased abundance of Hydrocortisone
CTD PMID:1666317, PMID:21466817, PMID:22100847 NCBI chr 3:113,661,712...113,668,558 JBrowse link
DDE term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CYP11A1 cytochrome P450, family 11, subfamily A, polypeptide 1 decreases expression
multiple interactions
EXP Dichlorodiphenyl Dichloroethylene results in decreased expression of CYP11A1 mRNA
Dichlorodiphenyl Dichloroethylene inhibits the reaction [Cholera Toxin results in increased expression of CYP11A1 mRNA]
CTD PMID:11226075 NCBI chr 7:59,172,829...59,188,479
Ensembl chr 7:59,175,758...59,188,478
JBrowse link
G CYP19A2 cytochrome P450 19A2 increases activity EXP Dichlorodiphenyl Dichloroethylene results in increased activity of CYP19A1 protein CTD PMID:18195494 NCBI chr 1:120,652,172...120,695,899
Ensembl chr 1:120,367,667...120,695,899
JBrowse link
deoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ACHE acetylcholinesterase increases activity EXP Deoxycholic Acid results in increased activity of ACHE protein CTD PMID:3697337 NCBI chr 3:8,732,451...8,738,274
Ensembl chr 3:8,732,324...8,739,149
JBrowse link
deoxynivalenol term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ACTB actin beta increases expression EXP deoxynivalenol results in increased expression of ACTB mRNA CTD PMID:26417708 NCBI chr 3:4,084,275...4,090,383
Ensembl chr 3:4,082,216...4,090,356
JBrowse link
G AKT1 AKT serine/threonine kinase 1 decreases expression
decreases phosphorylation
EXP deoxynivalenol results in decreased expression of AKT1 mRNA; deoxynivalenol results in decreased expression of AKT1 protein
deoxynivalenol results in decreased phosphorylation of AKT1 protein
CTD PMID:16099139, PMID:32229166
G ALB albumin decreases expression EXP deoxynivalenol results in decreased expression of ALB protein CTD PMID:19477247 NCBI chr 8:69,643,427...69,663,152
Ensembl chr 8:69,531,487...69,718,304
JBrowse link
G AXIN2 axin 2 increases expression EXP deoxynivalenol results in increased expression of AXIN2 protein CTD PMID:30690062 NCBI chr12:12,311,293...12,343,207
Ensembl chr12:12,311,293...12,343,200
JBrowse link
G BCL2 BCL2 apoptosis regulator decreases expression
multiple interactions
EXP deoxynivalenol results in decreased expression of BCL2 mRNA; deoxynivalenol results in decreased expression of BCL2 protein
[Acetylcysteine co-treated with fumonisin B1 co-treated with deoxynivalenol] results in increased expression of BCL2 protein; [Acetylcysteine co-treated with Zearalenone co-treated with deoxynivalenol] results in increased expression of BCL2 protein; [fumonisin B1 co-treated with deoxynivalenol] results in decreased expression of BCL2 mRNA; [fumonisin B1 co-treated with Zearalenone co-treated with deoxynivalenol] results in decreased expression of BCL2 protein; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in decreased expression of BCL2 mRNA]; Acetylcysteine inhibits the reaction [deoxynivalenol results in decreased expression of BCL2 protein]; fumonisin B1 inhibits the reaction [deoxynivalenol results in decreased expression of BCL2 protein]; fumonisin B1 inhibits the reaction [Zearalenone inhibits the reaction [deoxynivalenol results in decreased expression of BCL2 mRNA]]; Zearalenone inhibits the reaction [deoxynivalenol results in decreased expression of BCL2 mRNA]; Zearalenone inhibits the reaction [fumonisin B1 inhibits the reaction [deoxynivalenol results in decreased expression of BCL2 protein]]
CTD PMID:25701311, PMID:29109043 NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,288,544...158,518,879
JBrowse link
G BMI1 BMI1 proto-oncogene, polycomb ring finger decreases expression EXP deoxynivalenol results in decreased expression of BMI1 protein CTD PMID:30690062 NCBI chr10:52,586,089...52,596,154 JBrowse link
G CASP3 caspase 3 multiple interactions
increases expression
increases activity
EXP [fumonisin B1 co-treated with deoxynivalenol] results in increased expression of CASP3 mRNA; [fumonisin B1 co-treated with deoxynivalenol] results in increased expression of CASP3 protein; [fumonisin B1 co-treated with Zearalenone] promotes the reaction [deoxynivalenol results in increased expression of CASP3 protein]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with Zearalenone] promotes the reaction [deoxynivalenol results in increased expression of CASP3 protein]]; Acetylcysteine inhibits the reaction [deoxynivalenol promotes the reaction [[fumonisin B1 co-treated with Zearalenone] results in increased expression of CASP3 mRNA]]; Acetylcysteine inhibits the reaction [deoxynivalenol promotes the reaction [Zearalenone results in increased expression of CASP3 mRNA]]; Acetylcysteine inhibits the reaction [deoxynivalenol results in increased expression of CASP3 protein]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of CASP3 mRNA]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [deoxynivalenol results in increased expression of CASP3 mRNA]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [deoxynivalenol results in increased expression of CASP3 protein]]; deoxynivalenol promotes the reaction [[fumonisin B1 co-treated with Zearalenone] results in increased expression of CASP3 mRNA]; deoxynivalenol promotes the reaction [Zearalenone results in increased expression of CASP3 mRNA]; fumonisin B1 promotes the reaction [deoxynivalenol promotes the reaction [Zearalenone results in increased expression of CASP3 mRNA]]; fumonisin B1 promotes the reaction [Zearalenone promotes the reaction [deoxynivalenol results in increased expression of CASP3 mRNA]]; Zearalenone promotes the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of CASP3 mRNA]; Zearalenone promotes the reaction [deoxynivalenol results in increased expression of CASP3 mRNA]; Zearalenone promotes the reaction [deoxynivalenol results in increased expression of CASP3 protein]
deoxynivalenol results in increased expression of CASP3 mRNA; deoxynivalenol results in increased expression of CASP3 protein
deoxynivalenol results in increased activity of CASP3 protein
CTD PMID:20937367, PMID:24394488, PMID:29109043 NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,749...45,763,773
JBrowse link
G CCL2 chemokine (C-C motif) ligand 2 increases expression
multiple interactions
decreases expression
EXP deoxynivalenol results in increased expression of CCL2 mRNA
[deoxynivalenol co-treated with fumonisin B1] results in increased expression of CCL2 mRNA; [deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with fumonisin B1] results in increased expression of CCL2 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of CCL2 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone] results in increased expression of CCL2 mRNA; [deoxynivalenol co-treated with nivalenol] results in increased expression of CCL2 mRNA; [deoxynivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of CCL2 mRNA; [deoxynivalenol co-treated with Zearalenone] results in increased expression of CCL2 mRNA; fumonisin B1 metabolite inhibits the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA]; fumonisin B1 promotes the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA]
deoxynivalenol results in decreased expression of CCL2 mRNA
CTD PMID:23688591, PMID:30708112 NCBI chr12:40,798,109...40,800,013
Ensembl chr12:40,798,109...40,800,028
JBrowse link
G CCL20 C-C motif chemokine ligand 20 multiple interactions
increases expression
EXP [deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CCL20 mRNA; fumonisin B1 metabolite inhibits the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CCL20 mRNA]; fumonisin B1 promotes the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CCL20 mRNA]
deoxynivalenol results in increased expression of CCL20 mRNA
CTD PMID:23326479, PMID:30708112 NCBI chr15:129,172,743...129,176,069 JBrowse link
G CCND1 cyclin D1 decreases expression EXP deoxynivalenol results in decreased expression of CCND1 protein CTD PMID:30690062 NCBI chr 2:3,621,242...3,633,380
Ensembl chr 2:3,621,246...3,633,296
JBrowse link
G CCR6 C-C motif chemokine receptor 6 increases expression EXP deoxynivalenol results in increased expression of CCR6 mRNA CTD PMID:23326479 NCBI chr 1:2,016,600...2,034,172
Ensembl chr 1:2,018,608...2,019,821
JBrowse link
G CLDN3 claudin 3 decreases expression EXP deoxynivalenol analog results in decreased expression of CLDN3 protein; deoxynivalenol results in decreased expression of CLDN3 protein CTD PMID:19289138, PMID:22859312 NCBI chr 3:11,019,073...11,020,102
Ensembl chr 3:11,019,295...11,019,960
JBrowse link
G CLDN4 claudin 4 decreases expression EXP deoxynivalenol analog results in decreased expression of CLDN4 protein; deoxynivalenol results in decreased expression of CLDN4 protein CTD PMID:19289138, PMID:22859312 NCBI chr 3:11,039,711...11,053,930
Ensembl chr 3:11,039,706...11,053,925
JBrowse link
G CRP C-reactive protein, pentraxin-related decreases expression EXP deoxynivalenol results in decreased expression of CRP protein CTD PMID:25701311 NCBI chr 4:90,793,361...90,801,020
Ensembl chr 4:90,722,352...90,805,236
JBrowse link
G CTNNB1 catenin beta 1 decreases expression EXP deoxynivalenol results in decreased expression of CTNNB1 protein CTD PMID:30690062 NCBI chr13:25,163,550...25,208,314
Ensembl chr13:25,137,173...25,208,311
JBrowse link
G CX3CL1 C-X3-C motif chemokine ligand 1 increases expression EXP deoxynivalenol results in increased expression of CX3CL1 mRNA CTD PMID:23326479 NCBI chr 6:19,312,351...19,324,439 JBrowse link
G CXCL10 C-X-C motif chemokine ligand 10 increases expression EXP deoxynivalenol results in increased expression of CXCL10 mRNA CTD PMID:25701311 NCBI chr 8:71,693,641...71,695,948
Ensembl chr 8:71,693,339...71,695,948
JBrowse link
G CXCL8 C-X-C motif chemokine ligand 8 increases expression
decreases expression
multiple interactions
EXP deoxynivalenol results in increased expression of CXCL8 mRNA; deoxynivalenol results in increased expression of CXCL8 protein
deoxynivalenol results in decreased expression of CXCL8 protein
[deoxynivalenol co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; [deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CXCL8 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone] results in increased expression of CXCL8 mRNA; [deoxynivalenol co-treated with nivalenol] results in increased expression of CXCL8 mRNA; [deoxynivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; [deoxynivalenol co-treated with Zearalenone] results in increased expression of CXCL8 mRNA; deoxynivalenol promotes the reaction [nivalenol results in increased expression of CXCL8 mRNA]; fumonisin B1 metabolite inhibits the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CXCL8 mRNA]; fumonisin B1 promotes the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CXCL8 mRNA]
CTD PMID:23326479, PMID:23688591, PMID:25701311, PMID:26417708, PMID:27915442, PMID:30708112 NCBI chr 8:69,932,646...69,935,861
Ensembl chr 8:69,932,643...69,935,861
JBrowse link
G CYCS cytochrome c, somatic multiple interactions EXP [deoxynivalenol co-treated with fumonisin B1] results in increased expression of CYCS mRNA; Acetylcysteine inhibits the reaction [deoxynivalenol promotes the reaction [[Zearalenone co-treated with fumonisin B1] results in increased expression of CYCS mRNA]]; Acetylcysteine inhibits the reaction [deoxynivalenol promotes the reaction [Zearalenone results in increased expression of CYCS mRNA]]; Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [deoxynivalenol promotes the reaction [Zearalenone results in increased expression of CYCS mRNA]]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [[deoxynivalenol co-treated with fumonisin B1] results in increased expression of CYCS mRNA]]; deoxynivalenol promotes the reaction [[Zearalenone co-treated with fumonisin B1] results in increased expression of CYCS mRNA]; deoxynivalenol promotes the reaction [Zearalenone results in increased expression of CYCS mRNA]; fumonisin B1 promotes the reaction [deoxynivalenol promotes the reaction [Zearalenone results in increased expression of CYCS mRNA]]; Zearalenone promotes the reaction [[deoxynivalenol co-treated with fumonisin B1] results in increased expression of CYCS mRNA] CTD PMID:29109043 NCBI chr18:47,169,921...47,172,212
Ensembl chr18:47,169,866...47,173,866
JBrowse link
G CYP11A1 cytochrome P450, family 11, subfamily A, polypeptide 1 multiple interactions EXP deoxynivalenol inhibits the reaction [[FSHB protein co-treated with IGF1 protein] results in increased expression of CYP11A1 mRNA] CTD PMID:17656051 NCBI chr 7:59,172,829...59,188,479
Ensembl chr 7:59,175,758...59,188,478
JBrowse link
G CYP19A2 cytochrome P450 19A2 multiple interactions EXP deoxynivalenol inhibits the reaction [[FSHB protein co-treated with IGF1 protein] results in increased expression of CYP19A1 mRNA] CTD PMID:17656051 NCBI chr 1:120,652,172...120,695,899
Ensembl chr 1:120,367,667...120,695,899
JBrowse link
G DEFB1 defensin beta 1 decreases expression EXP deoxynivalenol results in decreased expression of DEFB1 mRNA CTD PMID:25701311
G DNMT3A DNA methyltransferase 3 alpha increases expression EXP deoxynivalenol results in increased expression of DNMT3A mRNA CTD PMID:26988607 NCBI chr 3:113,501,972...113,609,148
Ensembl chr 3:113,528,926...113,609,139
JBrowse link
G EIF4E eukaryotic translation initiation factor 4E decreases phosphorylation EXP deoxynivalenol results in decreased phosphorylation of EIF4E protein CTD PMID:16099139 NCBI chr 8:121,409,633...121,464,467
Ensembl chr 8:121,409,731...121,466,899
JBrowse link
G EIF4EBP1 eukaryotic translation initiation factor 4E binding protein 1 decreases expression EXP deoxynivalenol results in decreased expression of EIF4EBP1 protein modified form CTD PMID:16099139 NCBI chr15:48,423,001...48,443,373
Ensembl chr15:48,422,816...48,443,399
JBrowse link
G EZH2 enhancer of zeste 2 polycomb repressive complex 2 subunit increases expression EXP deoxynivalenol results in increased expression of EZH2 mRNA CTD PMID:26988607 NCBI chr 9:109,384,976...109,450,943
Ensembl chr 9:109,384,995...109,450,941
JBrowse link
G FSHB follicle stimulating hormone subunit beta multiple interactions EXP deoxynivalenol affects the reaction [[FSHB protein co-treated with IGF1 protein] results in increased abundance of Estradiol]; deoxynivalenol inhibits the reaction [[FSHB protein co-treated with IGF1 protein] results in increased abundance of Progesterone]; deoxynivalenol inhibits the reaction [[FSHB protein co-treated with IGF1 protein] results in increased expression of CYP11A1 mRNA]; deoxynivalenol inhibits the reaction [[FSHB protein co-treated with IGF1 protein] results in increased expression of CYP19A1 mRNA] CTD PMID:17656051 NCBI chr 2:30,395,769...30,399,282
Ensembl chr 2:30,395,018...30,399,274
JBrowse link
G GPX2 glutathione peroxidase 2 increases expression EXP deoxynivalenol results in increased expression of GPX2 mRNA CTD PMID:25701311 NCBI chr 7:89,007,636...89,011,620
Ensembl chr 7:89,007,369...89,011,620
JBrowse link
G GPX3 glutathione peroxidase 3 decreases expression EXP deoxynivalenol results in decreased expression of GPX3 mRNA CTD PMID:25701311 NCBI chr16:71,980,467...71,989,011
Ensembl chr16:71,980,475...71,989,026
JBrowse link
G GPX4 glutathione peroxidase 4 decreases expression EXP deoxynivalenol results in decreased expression of GPX4 mRNA CTD PMID:25701311 NCBI chr 2:77,321,568...77,323,931
Ensembl chr 2:77,320,464...77,323,886
JBrowse link
G GSK3B glycogen synthase kinase 3 beta increases expression EXP deoxynivalenol results in increased expression of GSK3B protein CTD PMID:30690062 NCBI chr13:140,136,109...140,370,197
Ensembl chr13:140,136,158...140,369,574
JBrowse link
G GSR glutathione-disulfide reductase decreases activity
multiple interactions
EXP deoxynivalenol results in decreased activity of GSR protein
Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]]; Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [Zearalenone promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [fumonisin B1 promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]]]; fumonisin B1 promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]; fumonisin B1 promotes the reaction [Zearalenone promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]]; Zearalenone promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]; Zearalenone promotes the reaction [fumonisin B1 promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]]
CTD PMID:29109043 NCBI chr15:54,382,564...54,433,989
Ensembl chr15:54,382,567...54,433,989
JBrowse link
G IFNB1 interferon beta 1 increases expression EXP deoxynivalenol results in increased expression of IFNB1 mRNA CTD PMID:24394488 NCBI chr 1:201,850,935...201,851,495
Ensembl chr 1:201,850,935...201,851,495
JBrowse link
G IFNG interferon gamma increases expression
decreases expression
multiple interactions
EXP deoxynivalenol results in increased expression of IFNG mRNA
deoxynivalenol results in decreased expression of IFNG mRNA
[Zearalenone co-treated with deoxynivalenol] results in decreased expression of IFNG mRNA
CTD PMID:18296887, PMID:18329193, PMID:25701311 NCBI chr 5:32,477,906...32,482,670
Ensembl chr 5:32,477,848...32,482,752
JBrowse link
G IGF1 insulin like growth factor 1 multiple interactions EXP deoxynivalenol affects the reaction [[FSHB protein co-treated with IGF1 protein] results in increased abundance of Estradiol]; deoxynivalenol affects the reaction [IGF1 protein results in increased abundance of Estradiol]; deoxynivalenol inhibits the reaction [[FSHB protein co-treated with IGF1 protein] results in increased abundance of Progesterone]; deoxynivalenol inhibits the reaction [[FSHB protein co-treated with IGF1 protein] results in increased expression of CYP11A1 mRNA]; deoxynivalenol inhibits the reaction [[FSHB protein co-treated with IGF1 protein] results in increased expression of CYP19A1 mRNA] CTD PMID:17656051 NCBI chr 5:81,762,027...81,909,253
Ensembl chr 5:81,775,970...81,848,037
JBrowse link
G IL10 interleukin 10 increases expression
multiple interactions
EXP deoxynivalenol results in increased expression of IL10 mRNA
deoxynivalenol promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL10 mRNA]
CTD PMID:19027837, PMID:19607891 NCBI chr 9:67,400,727...67,405,941
Ensembl chr 9:67,400,727...67,405,711
JBrowse link
G IL17A interleukin 17A multiple interactions
increases expression
EXP [deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of IL17A protein; deoxynivalenol promotes the reaction [nivalenol results in increased expression of IL17A mRNA]; fumonisin B1 inhibits the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of IL17A protein]; fumonisin B1 metabolite inhibits the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of IL17A protein]
deoxynivalenol results in increased expression of IL17A mRNA; deoxynivalenol results in increased expression of IL17A protein
CTD PMID:23326479, PMID:27915442, PMID:30708112 NCBI chr 7:46,013,584...46,017,161
Ensembl chr 7:46,013,584...46,017,153
JBrowse link
G IL1A interleukin 1 alpha increases expression
multiple interactions
decreases expression
EXP deoxynivalenol results in increased expression of IL1A mRNA; deoxynivalenol results in increased expression of IL1A protein
[deoxynivalenol co-treated with fumonisin B1] results in decreased expression of IL1A mRNA; [deoxynivalenol co-treated with nivalenol co-treated with fumonisin B1] results in increased expression of IL1A mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1A mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone] results in increased expression of IL1A mRNA; [deoxynivalenol co-treated with nivalenol] results in increased expression of IL1A mRNA; [deoxynivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1A mRNA; [deoxynivalenol co-treated with Zearalenone] results in decreased expression of IL1A mRNA; [deoxynivalenol co-treated with Zearalenone] results in increased expression of IL1A mRNA; deoxynivalenol promotes the reaction [nivalenol results in increased expression of IL1A mRNA]; nivalenol promotes the reaction [deoxynivalenol results in increased expression of IL1A mRNA]
deoxynivalenol results in decreased expression of IL1A mRNA
CTD PMID:23326479, PMID:23688591, PMID:27915442 NCBI chr 3:43,718,320...43,731,668
Ensembl chr 3:43,718,368...43,731,119
JBrowse link
G IL1B2 interleukin 1, beta 2 increases expression
multiple interactions
EXP deoxynivalenol results in increased expression of IL1B2 mRNA
deoxynivalenol promotes the reaction [nivalenol results in increased expression of IL1B2 mRNA]; nivalenol promotes the reaction [deoxynivalenol results in increased expression of IL1B2 mRNA]
CTD PMID:27915442
G IL2 interleukin 2 multiple interactions EXP [Zearalenone co-treated with deoxynivalenol] results in decreased expression of IL2 mRNA CTD PMID:18296887 NCBI chr 8:101,640,938...101,645,683
Ensembl chr 8:101,640,944...101,645,609
JBrowse link
G IL21 interleukin 21 increases expression EXP deoxynivalenol results in increased expression of IL21 mRNA CTD PMID:23326479 NCBI chr 8:101,532,742...101,540,712
Ensembl chr 8:101,530,949...101,540,738
JBrowse link
G IL22 interleukin 22 multiple interactions
increases expression
EXP deoxynivalenol promotes the reaction [nivalenol results in increased expression of IL22 mRNA]
deoxynivalenol results in increased expression of IL22 mRNA
CTD PMID:23326479, PMID:27915442 NCBI chr 5:32,599,522...32,604,507
Ensembl chr 5:32,599,301...32,604,736
JBrowse link
G IL23A interleukin 23 subunit alpha increases expression EXP deoxynivalenol results in increased expression of IL23A mRNA CTD PMID:23326479 NCBI chr 5:21,732,416...21,733,981
Ensembl chr 5:21,732,165...21,734,267
JBrowse link
G IL4 interleukin 4 increases expression EXP deoxynivalenol results in increased expression of IL4 mRNA CTD PMID:25701311 NCBI chr 2:134,986,817...134,994,365
Ensembl chr 2:134,986,817...134,994,365
JBrowse link
G IL6 interleukin 6 multiple interactions
increases expression
EXP [deoxynivalenol co-treated with fumonisin B1] results in increased expression of IL6 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with fumonisin B1] results in increased expression of IL6 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL6 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone] results in increased expression of IL6 mRNA; [deoxynivalenol co-treated with nivalenol] results in decreased expression of IL6 mRNA; [deoxynivalenol co-treated with nivalenol] results in increased expression of IL6 mRNA; [deoxynivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL6 mRNA; [deoxynivalenol co-treated with Zearalenone] results in increased expression of IL6 mRNA; deoxynivalenol affects the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL6 mRNA]; deoxynivalenol affects the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL6 protein]
deoxynivalenol results in increased expression of IL6 mRNA; deoxynivalenol results in increased expression of IL6 protein
CTD PMID:19027837, PMID:19607891, PMID:23326479, PMID:23688591, PMID:24394488 NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,340...91,511,263
JBrowse link
G LAMP2 lysosomal associated membrane protein 2 increases expression EXP deoxynivalenol results in increased expression of LAMP2 mRNA CTD PMID:26988607 NCBI chr  X:98,586,718...98,623,939
Ensembl chr  X:98,582,059...98,623,908
JBrowse link
G LOC110258578 interleukin-1 beta-like multiple interactions
increases expression
EXP [deoxynivalenol co-treated with fumonisin B1] results in increased expression of IL1B mRNA; [deoxynivalenol co-treated with nivalenol co-treated with fumonisin B1] results in increased expression of IL1B mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1B mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone] results in increased expression of IL1B mRNA; [deoxynivalenol co-treated with nivalenol] results in increased expression of IL1B mRNA; [deoxynivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1B mRNA; [deoxynivalenol co-treated with Zearalenone] results in increased expression of IL1B mRNA; deoxynivalenol promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL1B mRNA]
deoxynivalenol results in increased expression of IL1B mRNA
CTD PMID:19027837, PMID:23326479, PMID:23688591
G MAP1LC3A microtubule associated protein 1 light chain 3 alpha increases expression EXP deoxynivalenol results in increased expression of MAP1LC3A mRNA CTD PMID:32229166, PMID:32302720 NCBI chr17:37,957,830...37,959,505
Ensembl chr17:37,957,507...37,959,505
JBrowse link
G MAP1LC3B microtubule associated protein 1 light chain 3 beta increases expression EXP deoxynivalenol results in increased expression of MAP1LC3B mRNA CTD PMID:26988607 NCBI chr 6:1,919,879...1,941,069
Ensembl chr 6:1,915,387...1,941,077
JBrowse link
G MAPK1 mitogen-activated protein kinase 1 increases phosphorylation
decreases expression
increases activity
EXP deoxynivalenol analog results in increased phosphorylation of MAPK1 protein; deoxynivalenol results in increased phosphorylation of MAPK1 protein
deoxynivalenol results in decreased expression of MAPK1 protein modified form
deoxynivalenol results in increased activity of MAPK1 protein
CTD PMID:19674540, PMID:22859312, PMID:26988607 NCBI chr14:50,083,079...50,165,528
Ensembl chr14:50,082,896...50,165,523
JBrowse link
G MAPK3 mitogen-activated protein kinase 3 decreases expression
increases activity
increases phosphorylation
EXP deoxynivalenol results in decreased expression of MAPK3 protein modified form
deoxynivalenol results in increased activity of MAPK3 protein
deoxynivalenol analog results in increased phosphorylation of MAPK3 protein; deoxynivalenol results in increased phosphorylation of MAPK3 protein
CTD PMID:19674540, PMID:22859312, PMID:26988607 NCBI chr 3:18,291,444...18,299,410
Ensembl chr 3:18,291,445...18,299,567
JBrowse link
G MFN1 mitofusin 1 decreases expression EXP deoxynivalenol results in decreased expression of MFN1 protein CTD PMID:32302720 NCBI chr13:117,404,637...117,441,750
Ensembl chr13:117,404,699...117,442,481
JBrowse link
G MFN2 mitofusin 2 decreases expression EXP deoxynivalenol results in decreased expression of MFN2 protein CTD PMID:32302720 NCBI chr 6:72,026,512...72,056,439
Ensembl chr 6:72,026,722...72,056,439
JBrowse link
G MTOR mechanistic target of rapamycin kinase decreases expression
decreases phosphorylation
EXP deoxynivalenol results in decreased expression of MTOR mRNA
deoxynivalenol results in decreased phosphorylation of MTOR protein
CTD PMID:26988607, PMID:32229166 NCBI chr 6:71,286,989...71,412,913
Ensembl chr 6:71,286,989...71,412,888
JBrowse link
G MYC MYC proto-oncogene, bHLH transcription factor decreases expression EXP deoxynivalenol results in decreased expression of MYC protein CTD PMID:30690062 NCBI chr 4:12,455,141...12,460,360
Ensembl chr 4:12,455,119...12,461,078
JBrowse link
G NOS2 nitric oxide synthase 2 increases expression EXP deoxynivalenol results in increased expression of NOS2 mRNA CTD PMID:25701311 NCBI chr12:44,174,944...44,219,875
Ensembl chr12:44,174,944...44,327,111
JBrowse link
G OCLN occludin decreases expression EXP deoxynivalenol results in decreased expression of OCLN mRNA CTD PMID:25701311 NCBI chr16:47,600,175...47,652,435
Ensembl chr16:47,600,498...47,654,033
JBrowse link
G OPA1 OPA1 mitochondrial dynamin like GTPase decreases expression EXP deoxynivalenol results in decreased expression of OPA1 protein CTD PMID:32302720 NCBI chr13:130,624,771...130,718,345
Ensembl chr13:130,624,823...130,719,083
JBrowse link
G PCNA proliferating cell nuclear antigen decreases expression EXP deoxynivalenol results in decreased expression of PCNA protein CTD PMID:30690062 NCBI chr17:14,137,746...14,142,584
Ensembl chr17:14,125,814...14,185,276
JBrowse link
G PIK3CG phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma decreases expression EXP deoxynivalenol results in decreased expression of PIK3CG mRNA CTD PMID:32229166 NCBI chr 9:106,698,200...106,748,217
Ensembl chr 9:106,698,207...106,745,099
JBrowse link
G RPS6KB1 ribosomal protein S6 kinase B1 decreases expression
decreases phosphorylation
EXP deoxynivalenol results in decreased expression of RPS6KB1 mRNA
deoxynivalenol results in decreased phosphorylation of RPS6KB1 protein
CTD PMID:32229166 NCBI chr12:36,111,584...36,159,287 JBrowse link
G SETDB1 SET domain bifurcated histone lysine methyltransferase 1 increases expression EXP deoxynivalenol results in increased expression of SETDB1 mRNA CTD PMID:26988607 NCBI chr 4:98,259,801...98,293,238
Ensembl chr 4:98,260,373...98,293,096
JBrowse link
G SQSTM1 sequestosome 1 increases expression EXP deoxynivalenol results in increased expression of SQSTM1 mRNA CTD PMID:32302720 NCBI chr 2:78,752,768...78,763,998
Ensembl chr 2:78,752,768...78,784,256
JBrowse link
G STAT3 signal transducer and activator of transcription 3 increases expression EXP deoxynivalenol results in increased expression of STAT3 mRNA CTD PMID:23326479 NCBI chr12:20,407,316...20,471,091
Ensembl chr12:20,407,233...20,472,993
JBrowse link
G SUV39H2 suppressor of variegation 3-9 homolog 2 increases expression EXP deoxynivalenol results in increased expression of SUV39H2 mRNA CTD PMID:26988607 NCBI chr10:46,874,606...46,900,058
Ensembl chr10:46,862,584...46,900,040
JBrowse link
G TFF1 trefoil factor 1 affects expression EXP deoxynivalenol affects the expression of TFF1 mRNA CTD PMID:30854615 NCBI chr13:205,687,558...205,691,512 JBrowse link
G TFF2 trefoil factor 2 decreases expression EXP deoxynivalenol results in decreased expression of TFF2 mRNA CTD PMID:30854615 NCBI chr13:205,669,014...205,672,319
Ensembl chr13:205,669,014...205,672,324
JBrowse link
G TFF3 trefoil factor 3 decreases expression EXP deoxynivalenol results in decreased expression of TFF3 mRNA CTD PMID:30854615 NCBI chr13:205,641,038...205,644,333
Ensembl chr13:205,642,374...205,644,334
JBrowse link
G TGFB1 transforming growth factor beta 1 decreases expression
increases expression
EXP deoxynivalenol results in decreased expression of TGFB1 mRNA
deoxynivalenol results in increased expression of TGFB1 mRNA
CTD PMID:18329193, PMID:23326479 NCBI chr 6:49,332,169...49,348,642
Ensembl chr 6:49,332,169...49,349,048
JBrowse link
G TJP1 tight junction protein 1 increases expression
decreases expression
EXP deoxynivalenol results in increased expression of TJP1 mRNA
deoxynivalenol results in decreased expression of TJP1 protein
CTD PMID:20937367, PMID:26417708 NCBI chr 1:144,930,387...145,195,857
Ensembl chr 1:144,930,368...145,195,836
JBrowse link
G TNF tumor necrosis factor multiple interactions
increases expression
EXP [deoxynivalenol co-treated with fumonisin B1] results in increased expression of TNF mRNA; [deoxynivalenol co-treated with Lipopolysaccharides co-treated with fumonisin B1] results in increased expression of TNF mRNA; [deoxynivalenol co-treated with Lipopolysaccharides co-treated with fumonisin B1] results in increased expression of TNF protein; [deoxynivalenol co-treated with nivalenol co-treated with fumonisin B1] results in increased expression of TNF mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of TNF mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone] results in increased expression of TNF mRNA; [deoxynivalenol co-treated with nivalenol] results in increased expression of TNF mRNA; [deoxynivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of TNF mRNA; [deoxynivalenol co-treated with Zearalenone] results in increased expression of TNF mRNA; [Zearalenone co-treated with deoxynivalenol] results in decreased expression of TNF mRNA; deoxynivalenol promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF mRNA]; deoxynivalenol promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF protein]; lipopolysaccharide, Escherichia coli O111 B4 promotes the reaction [deoxynivalenol results in increased expression of TNF mRNA] CTD PMID:18296887, PMID:19027837, PMID:19607891, PMID:23326479, PMID:23688591, PMID:24394488, PMID:30708112 NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,636...23,703,655
JBrowse link
G TP53 tumor protein p53 multiple interactions EXP [deoxynivalenol co-treated with fumonisin B1] results in increased expression of TP53 mRNA; Acetylcysteine promotes the reaction [deoxynivalenol inhibits the reaction [Zearalenone results in increased expression of TP53 mRNA]]; deoxynivalenol inhibits the reaction [Zearalenone results in increased expression of TP53 mRNA]; fumonisin B1 inhibits the reaction [deoxynivalenol inhibits the reaction [Zearalenone results in increased expression of TP53 mRNA]]; Zearalenone promotes the reaction [[deoxynivalenol co-treated with fumonisin B1] results in increased expression of TP53 mRNA] CTD PMID:29109043 NCBI chr12:52,939,643...52,953,786
Ensembl chr12:52,939,643...52,953,819
JBrowse link
G VIM vimentin decreases expression EXP deoxynivalenol results in decreased expression of VIM mRNA CTD PMID:25701311 NCBI chr10:43,516,441...43,526,172
Ensembl chr10:43,517,307...43,526,172
JBrowse link
G XCR1 X-C motif chemokine receptor 1 increases expression EXP deoxynivalenol results in increased expression of XCR1 mRNA CTD PMID:23326479 NCBI chr13:29,150,376...29,233,802
Ensembl chr13:29,150,379...29,159,637
JBrowse link
dexamethasone term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ALPL alkaline phosphatase, biomineralization associated multiple interactions EXP 2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of ALPL mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of ALPL mRNA CTD PMID:30481989 NCBI chr 6:79,589,695...79,649,646
Ensembl chr 6:79,588,659...79,649,648
JBrowse link
G BCL2L1 BCL2 like 1 multiple interactions EXP [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of BCL2L1 mRNA CTD PMID:30481989 NCBI chr17:35,366,139...35,415,798
Ensembl chr17:35,366,141...35,415,359
JBrowse link
G CASP3 caspase 3 multiple interactions EXP [Troglitazone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CASP3 mRNA CTD PMID:30481989 NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,749...45,763,773
JBrowse link
G CEBPA CCAAT enhancer binding protein alpha increases expression
multiple interactions
EXP Dexamethasone results in increased expression of CEBPA mRNA
[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CEBPA mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CEBPA mRNA]
CTD PMID:11225715, PMID:30481989 NCBI chr 6:43,083,200...43,085,884
Ensembl chr 6:43,083,203...43,085,836
JBrowse link
G COL1A1 collagen type I alpha 1 chain multiple interactions EXP 2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of COL1A1 mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of COL1A1 mRNA CTD PMID:30481989 NCBI chr12:26,379,087...26,397,180
Ensembl chr12:26,379,090...26,397,003
JBrowse link
G CTNNB1 catenin beta 1 multiple interactions EXP 2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CTNNB1 mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CTNNB1 mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CTNNB1 mRNA] CTD PMID:30481989 NCBI chr13:25,163,550...25,208,314
Ensembl chr13:25,137,173...25,208,311
JBrowse link
G CYP17A1 cytochrome P450 17A1 increases expression EXP Dexamethasone results in increased expression of CYP17A1 CTD PMID:19852296 NCBI chr14:113,805,616...113,820,445
Ensembl chr14:113,805,611...113,812,041
JBrowse link
G FABP4 fatty acid binding protein 4, adipocyte multiple interactions EXP 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of FABP4 mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of FABP4 mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of FABP4 mRNA] CTD PMID:30481989 NCBI chr 4:55,096,400...55,101,209
Ensembl chr 4:55,096,404...55,101,897
JBrowse link
G IGF1 insulin like growth factor 1 multiple interactions EXP [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of IGF1 mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of IGF1 mRNA] CTD PMID:30481989 NCBI chr 5:81,762,027...81,909,253
Ensembl chr 5:81,775,970...81,848,037
JBrowse link
G IGF1R insulin like growth factor 1 receptor multiple interactions EXP [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of IGF1R mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of IGF1R mRNA] CTD PMID:30481989 NCBI chr 1:137,383,623...137,691,038
Ensembl chr 1:137,387,925...137,690,666
JBrowse link
G IRS1 insulin receptor substrate 1 decreases expression EXP Dexamethasone results in decreased expression of IRS1 mRNA CTD PMID:19852296 NCBI chr15:128,245,846...128,307,321
Ensembl chr15:128,245,846...128,308,335
JBrowse link
G PPARG peroxisome proliferator activated receptor gamma increases expression
multiple interactions
EXP Dexamethasone results in increased expression of PPARG
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of PPARG mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of PPARG mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of PPARG mRNA]
CTD PMID:19852296, PMID:30481989 NCBI chr13:68,301,566...68,433,951
Ensembl chr13:68,302,655...68,433,947
JBrowse link
G RUNX2 RUNX family transcription factor 2 multiple interactions EXP 2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA CTD PMID:30481989 NCBI chr 7:40,106,581...40,353,304
Ensembl chr 7:40,106,513...40,459,686
JBrowse link
G SLC2A4 solute carrier family 2 member 4 decreases expression EXP Dexamethasone results in decreased expression of SLC2A4 mRNA; Dexamethasone results in decreased expression of SLC2A4 protein CTD PMID:19852296 NCBI chr12:52,628,746...52,634,965
Ensembl chr12:52,628,450...52,634,967
JBrowse link
G SPP1 secreted phosphoprotein 1 multiple interactions EXP 2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of SPP1 mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of SPP1 mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of SPP1 mRNA] CTD PMID:30481989 NCBI chr 8:131,077,786...131,085,334
Ensembl chr 8:131,077,786...131,085,340
JBrowse link
digitoxin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ATP1A1 ATPase Na+/K+ transporting subunit alpha 1 decreases activity EXP Digitoxin results in decreased activity of ATP1A1 protein CTD PMID:28438630 NCBI chr 4:104,353,506...104,384,321
Ensembl chr 4:104,353,506...104,384,606
JBrowse link
G CASP3 caspase 3 decreases cleavage EXP Digitoxin results in decreased cleavage of CASP3 protein CTD PMID:28438630 NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,749...45,763,773
JBrowse link
dihydroartemisinin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G BAX BCL2 associated X, apoptosis regulator increases expression EXP dihydroartemisinin results in increased expression of BAX mRNA CTD PMID:29309768 NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,187,260...54,228,144
JBrowse link
G BCL2 BCL2 apoptosis regulator decreases expression EXP dihydroartemisinin results in decreased expression of BCL2 mRNA CTD PMID:29309768 NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,288,544...158,518,879
JBrowse link
G CASP3 caspase 3 increases expression EXP dihydroartemisinin results in increased expression of CASP3 mRNA CTD PMID:29309768 NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,749...45,763,773
JBrowse link
G MAPK1 mitogen-activated protein kinase 1 decreases phosphorylation EXP dihydroartemisinin results in decreased phosphorylation of MAPK1 protein CTD PMID:29309768 NCBI chr14:50,083,079...50,165,528
Ensembl chr14:50,082,896...50,165,523
JBrowse link
G MAPK3 mitogen-activated protein kinase 3 decreases phosphorylation EXP dihydroartemisinin results in decreased phosphorylation of MAPK3 protein CTD PMID:29309768 NCBI chr 3:18,291,444...18,299,410
Ensembl chr 3:18,291,445...18,299,567
JBrowse link
doxorubicin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G HSPA1L heat shock protein family A (Hsp70) member 1 like increases expression EXP Doxorubicin results in increased expression of HSPA1A protein CTD PMID:15810080 NCBI chr 7:23,909,960...23,938,678
Ensembl chr 7:23,909,960...23,921,723
JBrowse link
G MMP1 matrix metallopeptidase 1 increases activity
increases expression
EXP Doxorubicin results in increased activity of MMP1 protein
Doxorubicin results in increased expression of MMP1 mRNA
CTD PMID:19782292 NCBI chr 9:33,411,738...33,420,205
Ensembl chr 9:33,411,065...33,454,000
JBrowse link
G MMP14 matrix metallopeptidase 14 increases expression
increases activity
EXP Doxorubicin results in increased expression of MMP14 mRNA
Doxorubicin results in increased activity of MMP14 protein
CTD PMID:19782292 NCBI chr 7:76,174,502...76,185,931
Ensembl chr 7:76,174,500...76,185,923
JBrowse link
G MMP2 matrix metallopeptidase 2 increases expression
increases activity
EXP Doxorubicin results in increased expression of MMP2 mRNA
Doxorubicin results in increased activity of MMP2 protein
CTD PMID:19782292 NCBI chr 6:30,059,247...30,087,031
Ensembl chr 6:30,058,594...30,086,982
JBrowse link
G MMP9 matrix metallopeptidase 9 increases expression
increases activity
EXP Doxorubicin results in increased expression of MMP9 mRNA
Doxorubicin results in increased activity of MMP9 protein
CTD PMID:19782292 NCBI chr17:48,179,690...48,186,782
Ensembl chr17:48,175,056...48,188,264
JBrowse link
G TNF tumor necrosis factor decreases expression EXP Doxorubicin results in decreased expression of TNF mRNA CTD PMID:15810080 NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,636...23,703,655
JBrowse link
doxycycline term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G SLCO1A2 solute carrier organic anion transporter family member 1A2 increases uptake
multiple interactions
EXP SLCO1A2 protein results in increased uptake of Doxycycline
Doxycycline inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; Doxycycline inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]
CTD PMID:31287969 NCBI chr 5:52,020,303...52,133,132
Ensembl chr 5:52,037,218...52,131,789
JBrowse link
eplerenone term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G NFE2L2 nuclear factor, erythroid 2 like 2 multiple interactions EXP Eplerenone inhibits the reaction [Aldosterone results in increased activity of NFE2L2 protein] CTD PMID:24512358 NCBI chr15:82,967,485...83,146,185
Ensembl chr15:82,973,648...83,146,183
JBrowse link
estrone 3-sulfate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G SLCO1A2 solute carrier organic anion transporter family member 1A2 increases uptake
multiple interactions
EXP SLCO1A2 protein results in increased uptake of estrone sulfate
Amoxicillin inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; cefquinome inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; Chlortetracycline inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; Clarithromycin inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; daidzein inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; Doxycycline inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; epigallocatechin gallate inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; Erythromycin inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; Genistein inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; naringin inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; Oxytetracycline inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; Penicillins inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; Tetracycline inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; tilmicosin inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; Tylosin inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]
CTD PMID:31287969 NCBI chr 5:52,020,303...52,133,132
Ensembl chr 5:52,037,218...52,131,789
JBrowse link
ethylenediaminetetraacetic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ANPEP alanyl aminopeptidase, membrane multiple interactions EXP Edetic Acid promotes the reaction [1,10-phenanthroline results in decreased activity of ANPEP protein] CTD PMID:17109655 NCBI chr 7:55,351,081...55,373,856
Ensembl chr 7:55,351,083...55,373,881
JBrowse link
G LTA4H leukotriene A4 hydrolase decreases activity EXP Edetic Acid results in decreased activity of LTA4H protein CTD PMID:21670530 NCBI chr 5:87,486,552...87,518,520
Ensembl chr 5:87,486,512...87,518,515
JBrowse link
flutamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G GJA1 gap junction protein alpha 1 affects expression EXP Flutamide affects the expression of GJA1 mRNA CTD PMID:20961722 NCBI chr 1:40,988,818...41,002,129
Ensembl chr 1:40,988,515...41,002,137
JBrowse link
fulvestrant term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G HOXA10 homeobox A10 decreases expression
multiple interactions
EXP Fulvestrant results in decreased expression of HOXA10 mRNA
Fulvestrant inhibits the reaction [Estradiol results in increased expression of HOXA10 mRNA]
CTD PMID:21705055 NCBI chr18:45,393,525...45,403,259
Ensembl chr18:45,393,712...45,403,257
JBrowse link
G NOS3 nitric oxide synthase 3 multiple interactions EXP Fulvestrant inhibits the reaction [Estradiol results in increased phosphorylation of NOS3 protein]; Fulvestrant inhibits the reaction [Raloxifene Hydrochloride results in increased phosphorylation of NOS3 protein] CTD PMID:17618301 NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,156...6,228,938
JBrowse link
G PTGS2 prostaglandin-endoperoxide synthase 2 multiple interactions EXP Fulvestrant inhibits the reaction [Estradiol results in increased expression of PTGS2 mRNA] CTD PMID:21705055 NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,013...127,858,884
JBrowse link
fumonisin B1 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G AGER advanced glycosylation end-product specific receptor increases expression EXP fumonisin B1 results in increased expression of AGER mRNA CTD PMID:32198028 NCBI chr 7:24,218,116...24,221,162
Ensembl chr 7:24,218,116...24,228,756
JBrowse link
G BCL2 BCL2 apoptosis regulator multiple interactions EXP [Acetylcysteine co-treated with fumonisin B1 co-treated with deoxynivalenol] results in increased expression of BCL2 protein; [Acetylcysteine co-treated with fumonisin B1] results in increased expression of BCL2 protein; [Acetylcysteine co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of BCL2 protein; [fumonisin B1 co-treated with deoxynivalenol] results in decreased expression of BCL2 mRNA; [fumonisin B1 co-treated with Zearalenone co-treated with deoxynivalenol] results in decreased expression of BCL2 protein; [fumonisin B1 co-treated with Zearalenone] results in decreased expression of BCL2 mRNA; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in decreased expression of BCL2 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with Zearalenone] results in decreased expression of BCL2 mRNA]; Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [Zearalenone results in decreased expression of BCL2 mRNA]]; fumonisin B1 inhibits the reaction [deoxynivalenol results in decreased expression of BCL2 protein]; fumonisin B1 inhibits the reaction [Zearalenone inhibits the reaction [deoxynivalenol results in decreased expression of BCL2 mRNA]]; fumonisin B1 promotes the reaction [Zearalenone results in decreased expression of BCL2 mRNA]; Zearalenone inhibits the reaction [fumonisin B1 inhibits the reaction [deoxynivalenol results in decreased expression of BCL2 protein]]; Zearalenone inhibits the reaction [fumonisin B1 promotes the reaction [Zearalenone results in decreased expression of BCL2 mRNA]] CTD PMID:29109043 NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,288,544...158,518,879
JBrowse link
G CASP10 caspase 10 multiple interactions
increases expression
EXP 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of CASP10 mRNA] CTD PMID:32198028 NCBI chr15:104,858,082...104,895,941
Ensembl chr15:104,858,100...104,894,933
JBrowse link
G CASP3 caspase 3 multiple interactions
increases expression
EXP 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of CASP3 mRNA]; 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of CASP3 protein]; [fumonisin B1 co-treated with deoxynivalenol] results in increased expression of CASP3 mRNA; [fumonisin B1 co-treated with deoxynivalenol] results in increased expression of CASP3 protein; [fumonisin B1 co-treated with Zearalenone] promotes the reaction [deoxynivalenol results in increased expression of CASP3 protein]; [fumonisin B1 co-treated with Zearalenone] results in increased expression of CASP3 mRNA; [fumonisin B1 co-treated with Zearalenone] results in increased expression of CASP3 protein; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with Zearalenone] promotes the reaction [deoxynivalenol results in increased expression of CASP3 protein]]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with Zearalenone] results in increased expression of CASP3 protein]; Acetylcysteine inhibits the reaction [deoxynivalenol promotes the reaction [[fumonisin B1 co-treated with Zearalenone] results in increased expression of CASP3 mRNA]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of CASP3 mRNA]]; deoxynivalenol promotes the reaction [[fumonisin B1 co-treated with Zearalenone] results in increased expression of CASP3 mRNA]; fumonisin B1 promotes the reaction [deoxynivalenol promotes the reaction [Zearalenone results in increased expression of CASP3 mRNA]]; fumonisin B1 promotes the reaction [Zearalenone promotes the reaction [deoxynivalenol results in increased expression of CASP3 mRNA]]; Zearalenone promotes the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of CASP3 mRNA]
fumonisin B1 results in increased expression of CASP3 mRNA; fumonisin B1 results in increased expression of CASP3 protein
CTD PMID:29109043, PMID:32198028 NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,749...45,763,773
JBrowse link
G CASP8 caspase 8 multiple interactions
increases expression
EXP 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of CASP8 mRNA] CTD PMID:32198028 NCBI chr15:104,923,659...104,948,470
Ensembl chr15:104,923,953...104,948,470
JBrowse link
G CCL2 chemokine (C-C motif) ligand 2 multiple interactions
decreases expression
increases expression
EXP [deoxynivalenol co-treated with fumonisin B1] results in increased expression of CCL2 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with fumonisin B1] results in increased expression of CCL2 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of CCL2 mRNA; [deoxynivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of CCL2 mRNA; [nivalenol co-treated with fumonisin B1] results in increased expression of CCL2 mRNA; [Zearalenone co-treated with fumonisin B1] results in increased expression of CCL2 mRNA; fumonisin B1 metabolite inhibits the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA]; fumonisin B1 promotes the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA]
fumonisin B1 results in decreased expression of CCL2 mRNA
fumonisin B1 metabolite results in increased expression of CCL2 mRNA; fumonisin B1 results in increased expression of CCL2 mRNA
CTD PMID:23688591, PMID:30708112 NCBI chr12:40,798,109...40,800,013
Ensembl chr12:40,798,109...40,800,028
JBrowse link
G CCL20 C-C motif chemokine ligand 20 increases expression
multiple interactions
EXP fumonisin B1 results in increased expression of CCL20 mRNA
fumonisin B1 metabolite inhibits the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CCL20 mRNA]; fumonisin B1 promotes the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CCL20 mRNA]
CTD PMID:30708112 NCBI chr15:129,172,743...129,176,069 JBrowse link
G CHUK component of inhibitor of nuclear factor kappa B kinase complex increases expression EXP fumonisin B1 results in increased expression of CHUK mRNA CTD PMID:32198028 NCBI chr14:111,316,178...111,351,669
Ensembl chr14:111,307,610...111,351,712
JBrowse link
G CLDN1 claudin 1 decreases expression EXP fumonisin B1 results in decreased expression of CLDN1 mRNA; fumonisin B1 results in decreased expression of CLDN1 protein CTD PMID:31557363 NCBI chr13:127,714,857...127,730,628
Ensembl chr13:127,712,767...127,730,657
JBrowse link
G CXCL8 C-X-C motif chemokine ligand 8 multiple interactions
increases expression
EXP [deoxynivalenol co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; [deoxynivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; [nivalenol co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; [nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; [Zearalenone co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; fumonisin B1 metabolite inhibits the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CXCL8 mRNA]; fumonisin B1 promotes the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CXCL8 mRNA]
fumonisin B1 results in increased expression of CXCL8 mRNA
CTD PMID:23688591, PMID:30708112 NCBI chr 8:69,932,646...69,935,861
Ensembl chr 8:69,932,643...69,935,861
JBrowse link
G CYCS cytochrome c, somatic multiple interactions EXP [deoxynivalenol co-treated with fumonisin B1] results in increased expression of CYCS mRNA; [Zearalenone co-treated with fumonisin B1] results in increased expression of CYCS mRNA; Acetylcysteine inhibits the reaction [deoxynivalenol promotes the reaction [[Zearalenone co-treated with fumonisin B1] results in increased expression of CYCS mRNA]]; Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [deoxynivalenol promotes the reaction [Zearalenone results in increased expression of CYCS mRNA]]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [[deoxynivalenol co-treated with fumonisin B1] results in increased expression of CYCS mRNA]]; deoxynivalenol promotes the reaction [[Zearalenone co-treated with fumonisin B1] results in increased expression of CYCS mRNA]; fumonisin B1 promotes the reaction [deoxynivalenol promotes the reaction [Zearalenone results in increased expression of CYCS mRNA]]; Zearalenone promotes the reaction [[deoxynivalenol co-treated with fumonisin B1] results in increased expression of CYCS mRNA] CTD PMID:29109043 NCBI chr18:47,169,921...47,172,212
Ensembl chr18:47,169,866...47,173,866
JBrowse link
G GSR glutathione-disulfide reductase multiple interactions EXP Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]]; Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [Zearalenone promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [fumonisin B1 promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]]]; fumonisin B1 promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]; fumonisin B1 promotes the reaction [Zearalenone promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]]; Zearalenone promotes the reaction [fumonisin B1 promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]] CTD PMID:29109043 NCBI chr15:54,382,564...54,433,989
Ensembl chr15:54,382,567...54,433,989
JBrowse link
G IFNG interferon gamma decreases expression EXP fumonisin B1 metabolite results in decreased expression of IFNG protein CTD PMID:30708112 NCBI chr 5:32,477,906...32,482,670
Ensembl chr 5:32,477,848...32,482,752
JBrowse link
G IL17A interleukin 17A multiple interactions EXP fumonisin B1 inhibits the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of IL17A protein]; fumonisin B1 metabolite inhibits the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of IL17A protein] CTD PMID:30708112 NCBI chr 7:46,013,584...46,017,161
Ensembl chr 7:46,013,584...46,017,153
JBrowse link
G IL1A interleukin 1 alpha multiple interactions
increases expression
decreases expression
EXP [deoxynivalenol co-treated with fumonisin B1] results in decreased expression of IL1A mRNA; [deoxynivalenol co-treated with nivalenol co-treated with fumonisin B1] results in increased expression of IL1A mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1A mRNA; [deoxynivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1A mRNA; [nivalenol co-treated with fumonisin B1] results in increased expression of IL1A mRNA; [nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1A mRNA; [Zearalenone co-treated with fumonisin B1] results in increased expression of IL1A mRNA
fumonisin B1 results in increased expression of IL1A mRNA
fumonisin B1 results in decreased expression of IL1A mRNA
CTD PMID:23688591 NCBI chr 3:43,718,320...43,731,668
Ensembl chr 3:43,718,368...43,731,119
JBrowse link
G IL6 interleukin 6 multiple interactions
decreases expression
increases expression
EXP [deoxynivalenol co-treated with fumonisin B1] results in increased expression of IL6 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with fumonisin B1] results in increased expression of IL6 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL6 mRNA; [deoxynivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL6 mRNA; [nivalenol co-treated with fumonisin B1] results in decreased expression of IL6 mRNA; [nivalenol co-treated with fumonisin B1] results in increased expression of IL6 mRNA; [nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL6 mRNA; [Zearalenone co-treated with fumonisin B1] results in increased expression of IL6 mRNA
fumonisin B1 results in decreased expression of IL6 mRNA
fumonisin B1 results in increased expression of IL6 mRNA
CTD PMID:23688591, PMID:30708112 NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,340...91,511,263
JBrowse link
G LOC110258578 interleukin-1 beta-like increases expression
multiple interactions
EXP fumonisin B1 results in increased expression of IL1B mRNA
[deoxynivalenol co-treated with fumonisin B1] results in increased expression of IL1B mRNA; [deoxynivalenol co-treated with nivalenol co-treated with fumonisin B1] results in increased expression of IL1B mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1B mRNA; [deoxynivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1B mRNA; [nivalenol co-treated with fumonisin B1] results in increased expression of IL1B mRNA; [nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1B mRNA; [Zearalenone co-treated with fumonisin B1] results in increased expression of IL1B mRNA
CTD PMID:23688591
G MAP3K14 mitogen-activated protein kinase kinase kinase 14 increases expression EXP fumonisin B1 results in increased expression of MAP3K14 mRNA CTD PMID:32198028 NCBI chr12:18,142,899...18,182,931
Ensembl chr12:18,142,922...18,184,641
JBrowse link
G MAPK1 mitogen-activated protein kinase 1 increases phosphorylation EXP fumonisin B1 results in increased phosphorylation of MAPK1 protein CTD PMID:31557363 NCBI chr14:50,083,079...50,165,528
Ensembl chr14:50,082,896...50,165,523
JBrowse link
G MAPK10 mitogen-activated protein kinase 10 increases expression
multiple interactions
EXP fumonisin B1 results in increased expression of MAPK10 mRNA
3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of MAPK10 mRNA]
CTD PMID:32198028 NCBI chr 8:132,445,818...132,751,575
Ensembl chr 8:132,249,635...132,776,820
JBrowse link
G MAPK3 mitogen-activated protein kinase 3 increases phosphorylation EXP fumonisin B1 results in increased phosphorylation of MAPK3 protein CTD PMID:31557363 NCBI chr 3:18,291,444...18,299,410
Ensembl chr 3:18,291,445...18,299,567
JBrowse link
G MAPK8 mitogen-activated protein kinase 8 increases expression
multiple interactions
EXP fumonisin B1 results in increased expression of MAPK8 mRNA; fumonisin B1 results in increased expression of MAPK8 protein
3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of MAPK8 mRNA]; 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of MAPK8 protein]
CTD PMID:32198028 NCBI chr14:88,988,914...89,108,875
Ensembl chr14:88,988,949...89,172,200
JBrowse link
G MAPK9 mitogen-activated protein kinase 9 increases expression
multiple interactions
EXP fumonisin B1 results in increased expression of MAPK9 mRNA
3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of MAPK9 mRNA]
CTD PMID:32198028 NCBI chr 2:78,338,466...78,399,108
Ensembl chr 2:78,338,369...78,399,105
JBrowse link
G MUC1 mucin 1, cell surface associated decreases expression EXP fumonisin B1 results in decreased expression of MUC1 mRNA CTD PMID:31557363 NCBI chr 4:94,626,317...94,631,194 JBrowse link
G MUC2 mucin 2, oligomeric mucus/gel-forming increases expression EXP fumonisin B1 results in increased expression of MUC2 mRNA CTD PMID:31557363 NCBI chr 2:689,363...719,542 JBrowse link
G NFKB1 nuclear factor kappa B subunit 1 increases expression
multiple interactions
EXP fumonisin B1 results in increased expression of NFKB1 mRNA; fumonisin B1 results in increased expression of NFKB1 protein
3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of NFKB1 mRNA]; 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of NFKB1 protein]
CTD PMID:32198028 NCBI chr 8:118,391,010...118,478,927
Ensembl chr 8:118,390,637...118,506,691
JBrowse link
G OCLN occludin decreases expression EXP fumonisin B1 results in decreased expression of OCLN mRNA; fumonisin B1 results in decreased expression of OCLN protein CTD PMID:31557363 NCBI chr16:47,600,175...47,652,435
Ensembl chr16:47,600,498...47,654,033
JBrowse link
G TJP1 tight junction protein 1 decreases expression EXP fumonisin B1 results in decreased expression of TJP1 mRNA; fumonisin B1 results in decreased expression of TJP1 protein CTD PMID:31557363 NCBI chr 1:144,930,387...145,195,857
Ensembl chr 1:144,930,368...145,195,836
JBrowse link
G TNF tumor necrosis factor multiple interactions
increases expression
EXP [deoxynivalenol co-treated with fumonisin B1] results in increased expression of TNF mRNA; [deoxynivalenol co-treated with Lipopolysaccharides co-treated with fumonisin B1] results in increased expression of TNF mRNA; [deoxynivalenol co-treated with Lipopolysaccharides co-treated with fumonisin B1] results in increased expression of TNF protein; [deoxynivalenol co-treated with nivalenol co-treated with fumonisin B1] results in increased expression of TNF mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of TNF mRNA; [deoxynivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of TNF mRNA; [nivalenol co-treated with fumonisin B1] results in increased expression of TNF mRNA; [nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of TNF mRNA; [Zearalenone co-treated with fumonisin B1] results in increased expression of TNF mRNA
fumonisin B1 results in increased expression of TNF mRNA; fumonisin B1 results in increased expression of TNF protein
CTD PMID:23688591, PMID:30708112, PMID:32198028 NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,636...23,703,655
JBrowse link
G TP53 tumor protein p53 increases expression
multiple interactions
EXP fumonisin B1 results in increased expression of TP53 mRNA
[deoxynivalenol co-treated with fumonisin B1] results in increased expression of TP53 mRNA; Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [Zearalenone results in increased expression of TP53 mRNA]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [fumonisin B1 results in increased expression of TP53 mRNA]]; fumonisin B1 inhibits the reaction [deoxynivalenol inhibits the reaction [Zearalenone results in increased expression of TP53 mRNA]]; fumonisin B1 promotes the reaction [Zearalenone results in increased expression of TP53 mRNA]; Zearalenone promotes the reaction [[deoxynivalenol co-treated with fumonisin B1] results in increased expression of TP53 mRNA]; Zearalenone promotes the reaction [fumonisin B1 results in increased expression of TP53 mRNA]
CTD PMID:29109043 NCBI chr12:52,939,643...52,953,786
Ensembl chr12:52,939,643...52,953,819
JBrowse link
G TRADD TNFRSF1A associated via death domain increases expression EXP fumonisin B1 results in increased expression of TRADD mRNA CTD PMID:32198028 NCBI chr 6:27,797,594...27,804,654
Ensembl chr 6:27,797,607...27,804,423
JBrowse link
G TRAF2 TNF receptor associated factor 2 increases expression EXP fumonisin B1 results in increased expression of TRAF2 mRNA CTD PMID:32198028
gamma-hexachlorocyclohexane term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CAT catalase decreases activity EXP Hexachlorocyclohexane results in decreased activity of CAT protein CTD PMID:16838206 NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452
JBrowse link
hypoxanthine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CAT catalase multiple interactions EXP CAT protein inhibits the reaction [[Hypoxanthine co-treated with XDH protein] results in increased chemical synthesis of Carbon Monoxide]; CAT protein results in decreased activity of [Hypoxanthine co-treated with XDH protein] CTD PMID:21984542 NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452
JBrowse link
G XDH xanthine dehydrogenase multiple interactions EXP [Hypoxanthine co-treated with XDH protein] results in increased chemical synthesis of Carbon Monoxide; [Hypoxanthine co-treated with XDH protein] results in increased chemical synthesis of Hydrogen Peroxide; [Hypoxanthine co-treated with XDH protein] results in increased chemical synthesis of Superoxides; CAT protein inhibits the reaction [[Hypoxanthine co-treated with XDH protein] results in increased chemical synthesis of Carbon Monoxide]; CAT protein results in decreased activity of [Hypoxanthine co-treated with XDH protein]; tempol inhibits the reaction [[Hypoxanthine co-treated with XDH protein] results in increased chemical synthesis of Carbon Monoxide]; tempol results in decreased activity of [Hypoxanthine co-treated with XDH protein] CTD PMID:21984542 NCBI chr 3:107,987,060...108,052,043
Ensembl chr 3:107,986,528...108,080,151
JBrowse link
imipramine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G FMO1 flavin containing dimethylaniline monoxygenase 1 increases oxidation EXP FMO1 protein results in increased oxidation of Imipramine CTD PMID:6439199 NCBI chr 9:63,860,957...63,895,086
Ensembl chr 9:63,812,103...63,895,077
JBrowse link
iodomethane term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G PGK1 phosphoglycerate kinase 1 increases alkylation EXP methyl iodide results in increased alkylation of PGK1 protein CTD PMID:6697999 NCBI chr  X:62,187,472...62,210,321
Ensembl chr  X:62,187,431...62,212,244
JBrowse link
lithocholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ACHE acetylcholinesterase increases activity EXP Lithocholic Acid results in increased activity of ACHE protein CTD PMID:3697337 NCBI chr 3:8,732,451...8,738,274
Ensembl chr 3:8,732,324...8,739,149
JBrowse link
G LRP2 LDL receptor related protein 2 affects expression
multiple interactions
EXP Lithocholic Acid affects the expression of LRP2 protein
Lithocholic Acid binds to and results in increased activity of LRP2 protein
CTD PMID:15375181 NCBI chr15:75,565,299...75,754,604
Ensembl chr15:75,565,301...75,716,694
JBrowse link
mesulergine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G HTR2C 5-hydroxytryptamine receptor 2C affects binding
multiple interactions
EXP mesulergine binds to HTR2C protein
8-fluoro-12-(4-methylpiperazin-1-yl)-6H-(1)benzothieno(2,3-b)(1,5)benzodiazepine inhibits the reaction [mesulergine binds to HTR2C protein]
CTD PMID:11927170 NCBI chr  X:94,053,415...94,313,352
Ensembl chr  X:94,053,456...94,313,356
JBrowse link
methoprene term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G GPD1 glycerol-3-phosphate dehydrogenase 1 increases activity EXP Methoprene results in increased activity of GPD1 protein CTD PMID:15583048 NCBI chr 5:16,008,179...16,021,676
Ensembl chr 5:16,007,448...16,017,825
JBrowse link
N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ANXA5 annexin A5 multiple interactions EXP N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid promotes the reaction [TNF protein results in increased activity of ANXA5 protein]]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein promotes the reaction [Linoleic Acid results in increased activity of ANXA5 protein]]; Zinc Acetate inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid promotes the reaction [TNF protein results in increased activity of ANXA5 protein]]]; Zinc Acetate inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein promotes the reaction [Linoleic Acid results in increased activity of ANXA5 protein]]] CTD PMID:10617950 NCBI chr 8:102,387,833...102,420,868
Ensembl chr 8:102,388,103...102,425,750
JBrowse link
G CASP3 caspase 3 multiple interactions EXP N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid promotes the reaction [TNF protein results in increased activity of CASP3 protein]]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid results in increased activity of CASP3 protein]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein promotes the reaction [Linoleic Acid results in increased activity of CASP3 protein]]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein results in increased activity of CASP3 protein]; Zinc Acetate inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid promotes the reaction [TNF protein results in increased activity of CASP3 protein]]]; Zinc Acetate inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid results in increased activity of CASP3 protein]]; Zinc Acetate inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein results in increased activity of CASP3 protein]]; Zinc Acetate promotes the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein promotes the reaction [Linoleic Acid results in increased activity of CASP3 protein]]] CTD PMID:10617950 NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,749...45,763,773
JBrowse link
G IL6 interleukin 6 multiple interactions
increases expression
EXP [Zinc co-treated with 2,4-thiazolidinedione] inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein results in increased expression of IL6 mRNA]]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein results in increased expression of IL6 mRNA]; Zinc inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased expression of IL6 protein] CTD PMID:14519784, PMID:15226458 NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,340...91,511,263
JBrowse link
G PPARA peroxisome proliferator activated receptor alpha decreases expression
multiple interactions
EXP N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in decreased expression of PPARA mRNA
Zinc Acetate inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in decreased expression of PPARA mRNA]
CTD PMID:18845708 NCBI chr 5:3,302,755...3,321,091
Ensembl chr 5:3,300,708...3,366,361
JBrowse link
G PPARG peroxisome proliferator activated receptor gamma multiple interactions EXP N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [Zinc results in increased expression of and results in increased activity of PPARG protein]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [Zinc results in increased expression of PPARG mRNA] CTD PMID:14519784 NCBI chr13:68,301,566...68,433,951
Ensembl chr13:68,302,655...68,433,947
JBrowse link
G PTGS2 prostaglandin-endoperoxide synthase 2 increases expression
multiple interactions
EXP N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased expression of PTGS2 mRNA; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased expression of PTGS2 protein
caffeic acid phenethyl ester inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased expression of PTGS2 protein]; Zinc Acetate inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased expression of PTGS2 mRNA]
CTD PMID:18845708 NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,013...127,858,884
JBrowse link
G SELE selectin E multiple interactions
increases expression
EXP Zinc Acetate inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased expression of SELE mRNA] CTD PMID:18845708 NCBI chr 4:81,289,061...81,299,657 JBrowse link
G TNF tumor necrosis factor multiple interactions
increases activity
EXP [2,4-thiazolidinedione co-treated with Zinc] inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased activity of TNF protein]; [ciprofibrate co-treated with Zinc] inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased activity of TNF protein]; [Fenofibrate co-treated with Zinc] inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased activity of TNF protein]; [Troglitazone co-treated with Zinc] inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased activity of TNF protein]; [Zinc co-treated with 2,4-thiazolidinedione] inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein results in increased expression of IL6 mRNA]]; [Zinc co-treated with 2,4-thiazolidinedione] inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein results in increased expression of VCAM1 mRNA]]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid promotes the reaction [TNF protein results in increased activity of ANXA5 protein]]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid promotes the reaction [TNF protein results in increased activity of CASP3 protein]]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein promotes the reaction [Linoleic Acid results in increased activity of ANXA5 protein]]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein promotes the reaction [Linoleic Acid results in increased activity of CASP3 protein]]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein results in increased activity of CASP3 protein]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein results in increased expression of IL6 mRNA]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein results in increased expression of VCAM1 mRNA]; Zinc Acetate inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid promotes the reaction [TNF protein results in increased activity of ANXA5 protein]]]; Zinc Acetate inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid promotes the reaction [TNF protein results in increased activity of CASP3 protein]]]; Zinc Acetate inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein promotes the reaction [Linoleic Acid results in increased activity of ANXA5 protein]]]; Zinc Acetate inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein results in increased activity of CASP3 protein]]; Zinc Acetate promotes the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein promotes the reaction [Linoleic Acid results in increased activity of CASP3 protein]]] CTD PMID:10617950, PMID:15226458 NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,636...23,703,655
JBrowse link
G VCAM1 vascular cell adhesion molecule 1 multiple interactions EXP [Zinc co-treated with 2,4-thiazolidinedione] inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein results in increased expression of VCAM1 mRNA]]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein results in increased expression of VCAM1 mRNA] CTD PMID:15226458 NCBI chr 4:117,496,914...117,511,211
Ensembl chr 4:117,496,908...117,511,226
JBrowse link
Nivalenol term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CCL2 chemokine (C-C motif) ligand 2 increases expression
multiple interactions
EXP nivalenol results in increased expression of CCL2 mRNA
[deoxynivalenol co-treated with nivalenol co-treated with fumonisin B1] results in increased expression of CCL2 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of CCL2 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone] results in increased expression of CCL2 mRNA; [deoxynivalenol co-treated with nivalenol] results in increased expression of CCL2 mRNA; [nivalenol co-treated with fumonisin B1] results in increased expression of CCL2 mRNA; [nivalenol co-treated with Zearalenone] results in increased expression of CCL2 mRNA
CTD PMID:23688591 NCBI chr12:40,798,109...40,800,013
Ensembl chr12:40,798,109...40,800,028
JBrowse link
G CXCL8 C-X-C motif chemokine ligand 8 increases expression
multiple interactions
EXP nivalenol results in increased expression of CXCL8 mRNA
[deoxynivalenol co-treated with nivalenol co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone] results in increased expression of CXCL8 mRNA; [deoxynivalenol co-treated with nivalenol] results in increased expression of CXCL8 mRNA; [nivalenol co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; [nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; [nivalenol co-treated with Zearalenone] results in increased expression of CXCL8 mRNA; deoxynivalenol promotes the reaction [nivalenol results in increased expression of CXCL8 mRNA]
CTD PMID:23688591, PMID:27915442 NCBI chr 8:69,932,646...69,935,861
Ensembl chr 8:69,932,643...69,935,861
JBrowse link
G IL17A interleukin 17A multiple interactions
increases expression
EXP deoxynivalenol promotes the reaction [nivalenol results in increased expression of IL17A mRNA] CTD PMID:27915442 NCBI chr 7:46,013,584...46,017,161
Ensembl chr 7:46,013,584...46,017,153
JBrowse link
G IL1A interleukin 1 alpha multiple interactions
increases expression
decreases expression
EXP [deoxynivalenol co-treated with nivalenol co-treated with fumonisin B1] results in increased expression of IL1A mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1A mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone] results in increased expression of IL1A mRNA; [deoxynivalenol co-treated with nivalenol] results in increased expression of IL1A mRNA; [nivalenol co-treated with fumonisin B1] results in increased expression of IL1A mRNA; [nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1A mRNA; [nivalenol co-treated with Zearalenone] results in decreased expression of IL1A mRNA; [nivalenol co-treated with Zearalenone] results in increased expression of IL1A mRNA; deoxynivalenol promotes the reaction [nivalenol results in increased expression of IL1A mRNA]; nivalenol promotes the reaction [deoxynivalenol results in increased expression of IL1A mRNA]
nivalenol results in decreased expression of IL1A mRNA
CTD PMID:23688591, PMID:27915442 NCBI chr 3:43,718,320...43,731,668
Ensembl chr 3:43,718,368...43,731,119
JBrowse link
G IL1B2 interleukin 1, beta 2 multiple interactions
increases expression
EXP deoxynivalenol promotes the reaction [nivalenol results in increased expression of IL1B2 mRNA]; nivalenol promotes the reaction [deoxynivalenol results in increased expression of IL1B2 mRNA] CTD PMID:27915442
G IL22 interleukin 22 multiple interactions
increases expression
EXP deoxynivalenol promotes the reaction [nivalenol results in increased expression of IL22 mRNA] CTD PMID:27915442 NCBI chr 5:32,599,522...32,604,507
Ensembl chr 5:32,599,301...32,604,736
JBrowse link
G IL6 interleukin 6 increases expression
decreases expression
multiple interactions
EXP nivalenol results in increased expression of IL6 mRNA
nivalenol results in decreased expression of IL6 mRNA
[deoxynivalenol co-treated with nivalenol co-treated with fumonisin B1] results in increased expression of IL6 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL6 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone] results in increased expression of IL6 mRNA; [deoxynivalenol co-treated with nivalenol] results in decreased expression of IL6 mRNA; [deoxynivalenol co-treated with nivalenol] results in increased expression of IL6 mRNA; [nivalenol co-treated with fumonisin B1] results in decreased expression of IL6 mRNA; [nivalenol co-treated with fumonisin B1] results in increased expression of IL6 mRNA; [nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL6 mRNA; [nivalenol co-treated with Zearalenone] results in decreased expression of IL6 mRNA; [nivalenol co-treated with Zearalenone] results in increased expression of IL6 mRNA
CTD PMID:23688591 NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,340...91,511,263
JBrowse link
G LOC110258578 interleukin-1 beta-like increases expression
multiple interactions
EXP nivalenol results in increased expression of IL1B mRNA
[deoxynivalenol co-treated with nivalenol co-treated with fumonisin B1] results in increased expression of IL1B mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1B mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone] results in increased expression of IL1B mRNA; [deoxynivalenol co-treated with nivalenol] results in increased expression of IL1B mRNA; [nivalenol co-treated with fumonisin B1] results in increased expression of IL1B mRNA; [nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1B mRNA; [nivalenol co-treated with Zearalenone] results in increased expression of IL1B mRNA
CTD PMID:23688591
G TNF tumor necrosis factor increases expression
multiple interactions
EXP nivalenol results in increased expression of TNF mRNA
[deoxynivalenol co-treated with nivalenol co-treated with fumonisin B1] results in increased expression of TNF mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of TNF mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone] results in increased expression of TNF mRNA; [deoxynivalenol co-treated with nivalenol] results in increased expression of TNF mRNA; [nivalenol co-treated with fumonisin B1] results in increased expression of TNF mRNA; [nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of TNF mRNA; [nivalenol co-treated with Zearalenone] results in increased expression of TNF mRNA
CTD PMID:23688591 NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,636...23,703,655
JBrowse link
norflurazon term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CYP2C49 cytochrome P450 2C49 multiple interactions EXP CYP2C49 protein results in increased metabolism of and results in decreased susceptibility to norflurazone CTD PMID:16315095 NCBI chr14:106,571,803...106,612,082 JBrowse link
notoginsenoside R1 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G IL10 interleukin 10 decreases expression EXP notoginsenoside R1 results in decreased expression of IL10 protein CTD PMID:25721049 NCBI chr 9:67,400,727...67,405,941
Ensembl chr 9:67,400,727...67,405,711
JBrowse link
G IL4 interleukin 4 decreases expression EXP notoginsenoside R1 results in decreased expression of IL4 protein CTD PMID:25721049 NCBI chr 2:134,986,817...134,994,365
Ensembl chr 2:134,986,817...134,994,365
JBrowse link
ochratoxin A term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G AKT1 AKT serine/threonine kinase 1 decreases phosphorylation EXP ochratoxin A results in decreased phosphorylation of AKT1 protein CTD PMID:30287338
G ANXA5 annexin A5 decreases expression EXP ochratoxin A results in decreased expression of ANXA5 mRNA CTD PMID:14994279 NCBI chr 8:102,387,833...102,420,868
Ensembl chr 8:102,388,103...102,425,750
JBrowse link
G ATG5 autophagy related 5 multiple interactions
increases expression
EXP ATG5 protein affects the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; ATG5 protein affects the reaction [ochratoxin A results in increased cleavage of PARP1 protein]
ochratoxin A results in increased expression of ATG5 protein
CTD PMID:28699257, PMID:30287338 NCBI chr 1:72,343,950...72,520,402
Ensembl chr 1:72,270,799...72,520,453
JBrowse link
G BCL2 BCL2 apoptosis regulator decreases expression
affects expression
multiple interactions
EXP ochratoxin A results in decreased expression of BCL2 mRNA
ochratoxin A affects the expression of BCL2 mRNA
TLR4 protein affects the reaction [ochratoxin A affects the expression of BCL2 mRNA]
CTD PMID:28528741, PMID:29080797 NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,288,544...158,518,879
JBrowse link
G BECN1 beclin 1 multiple interactions
increases expression
EXP BECN1 protein affects the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; BECN1 protein affects the reaction [ochratoxin A results in increased cleavage of PARP1 protein]
ochratoxin A results in increased expression of BECN1 protein
CTD PMID:30287338 NCBI chr12:20,041,914...20,054,249
Ensembl chr12:20,041,956...20,054,373
JBrowse link
G BRCA1 BRCA1 DNA repair associated increases expression EXP ochratoxin A results in increased expression of BRCA1 protein CTD PMID:32454083 NCBI chr12:19,788,087...19,854,515
Ensembl chr12:19,786,020...19,855,570
JBrowse link
G CASP3 caspase 3 multiple interactions
increases cleavage
EXP 3-methyladenine promotes the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; ATG5 protein affects the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; BECN1 protein affects the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; Chloroquine promotes the reaction [ochratoxin A results in increased cleavage of CASP3 protein] CTD PMID:30287338 NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,749...45,763,773
JBrowse link
G CAT catalase decreases expression EXP ochratoxin A results in decreased expression of CAT protein CTD PMID:18547704 NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452
JBrowse link
G CRYAB crystallin alpha B increases expression EXP ochratoxin A results in increased expression of CRYAB mRNA CTD PMID:14994279 NCBI chr 9:39,638,505...39,643,530
Ensembl chr 9:39,638,502...39,643,530
JBrowse link
G CYP2A19 cytochrome P450 2A19 decreases expression EXP ochratoxin A results in decreased expression of CYP2A6 mRNA CTD PMID:14994279 NCBI chr 6:49,056,579...49,064,111
Ensembl chr 6:49,056,578...49,064,107
JBrowse link
G DAD1 defender against cell death 1 decreases expression EXP ochratoxin A results in decreased expression of DAD1 mRNA CTD PMID:14994279 NCBI chr 7:76,432,040...76,457,403
Ensembl chr 7:76,432,029...76,457,192
JBrowse link
G DNMT1 DNA methyltransferase 1 increases expression
multiple interactions
EXP ochratoxin A results in increased expression of DNMT1 mRNA; ochratoxin A results in increased expression of DNMT1 protein
Decitabine inhibits the reaction [ochratoxin A results in increased expression of DNMT1 mRNA]; Decitabine inhibits the reaction [ochratoxin A results in increased expression of DNMT1 protein]
CTD PMID:29080797, PMID:30923867 NCBI chr 2:68,981,564...69,040,364
Ensembl chr 2:68,981,564...69,029,919
JBrowse link
G DNMT3A DNA methyltransferase 3 alpha increases expression EXP ochratoxin A results in increased expression of DNMT3A mRNA CTD PMID:29080797, PMID:30923867 NCBI chr 3:113,501,972...113,609,148
Ensembl chr 3:113,528,926...113,609,139
JBrowse link
G GCLC glutamate-cysteine ligase catalytic subunit decreases expression
multiple interactions
EXP ochratoxin A results in decreased expression of GCLC mRNA
ochratoxin A inhibits the reaction [sulforafan results in increased expression of GCLC mRNA]
CTD PMID:18547363 NCBI chr 7:27,209,565...27,253,535
Ensembl chr 7:27,209,564...27,253,535
JBrowse link
G GLMN glomulin, FKBP associated protein increases expression EXP ochratoxin A results in increased expression of GLMN mRNA CTD PMID:14994279 NCBI chr 4:124,773,957...124,813,336
Ensembl chr 4:124,773,979...124,813,337
JBrowse link
G HDAC1 histone deacetylase 1 multiple interactions
increases expression
EXP Panobinostat inhibits the reaction [ochratoxin A results in increased expression of HDAC1 mRNA]; Panobinostat inhibits the reaction [ochratoxin A results in increased expression of HDAC1 protein]
ochratoxin A results in increased expression of HDAC1 mRNA; ochratoxin A results in increased expression of HDAC1 protein
CTD PMID:29080797 NCBI chr 6:88,749,611...88,785,220
Ensembl chr 6:88,749,634...88,785,412
JBrowse link
G HSP90B1 heat shock protein 90 beta family member 1 increases expression
decreases expression
EXP ochratoxin A results in increased expression of HSP90B1 mRNA
ochratoxin A results in decreased expression of HSP90B1 mRNA
CTD PMID:14994279 NCBI chr 5:80,511,513...80,531,016
Ensembl chr 5:80,511,507...80,531,005
JBrowse link
G HSPA5 heat shock protein family A (Hsp70) member 5 increases expression EXP ochratoxin A results in increased expression of HSPA5 mRNA; ochratoxin A results in increased expression of HSPA5 protein CTD PMID:28699257 NCBI chr 1:265,930,044...265,934,959
Ensembl chr 1:265,930,045...265,934,904
JBrowse link
G HSPD1 heat shock protein family D (Hsp60) member 1 decreases expression EXP ochratoxin A results in decreased expression of HSPD1 mRNA CTD PMID:14994279 NCBI chr15:101,360,355...101,373,498
Ensembl chr15:101,360,094...101,373,527
JBrowse link
G ID2 inhibitor of DNA binding 2 decreases expression EXP ochratoxin A results in decreased expression of ID2 mRNA CTD PMID:14994279 NCBI chr 3:127,500,759...127,503,207
Ensembl chr 3:127,500,759...127,503,257
JBrowse link
G IGFBP2 insulin like growth factor binding protein 2 increases expression EXP ochratoxin A results in increased expression of IGFBP2 mRNA CTD PMID:14994279 NCBI chr15:118,822,092...118,850,985
Ensembl chr15:118,822,047...118,850,976
JBrowse link
G IL1A interleukin 1 alpha multiple interactions EXP ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of IL1A mRNA]; TLR4 protein affects the reaction [ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of IL1A mRNA]] CTD PMID:28528741 NCBI chr 3:43,718,320...43,731,668
Ensembl chr 3:43,718,368...43,731,119
JBrowse link
G IL2 interleukin 2 decreases secretion EXP ochratoxin A results in decreased secretion of IL2 protein CTD PMID:28699257 NCBI chr 8:101,640,938...101,645,683
Ensembl chr 8:101,640,944...101,645,609
JBrowse link
G IL4 interleukin 4 increases expression EXP ochratoxin A results in increased expression of IL4 mRNA CTD PMID:14994279 NCBI chr 2:134,986,817...134,994,365
Ensembl chr 2:134,986,817...134,994,365
JBrowse link
G IL6 interleukin 6 increases expression
multiple interactions
EXP ochratoxin A results in increased expression of IL6 mRNA
NFE2L2 protein affects the reaction [ochratoxin A results in increased expression of IL6 mRNA]
CTD PMID:28710020 NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,340...91,511,263
JBrowse link
G JAK2 Janus kinase 2 multiple interactions
increases phosphorylation
EXP Decitabine inhibits the reaction [ochratoxin A results in increased phosphorylation of JAK2 protein] CTD PMID:30923867 NCBI chr 1:216,849,744...217,002,310
Ensembl chr 1:216,848,686...217,002,148
JBrowse link
G LOC100522201 histone H2AX multiple interactions
increases expression
EXP alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [ochratoxin A results in increased expression of H2AX protein]; Decitabine inhibits the reaction [ochratoxin A results in increased expression of H2AX protein]; STAT3 protein affects the reaction [ochratoxin A results in increased expression of H2AX protein] CTD PMID:30923867 NCBI chr 9:46,308,824...46,310,494
Ensembl chr 9:46,309,653...46,310,084
JBrowse link
G MAPK1 mitogen-activated protein kinase 1 increases phosphorylation
multiple interactions
EXP ochratoxin A results in increased phosphorylation of MAPK1 protein
ochratoxin A inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]
CTD PMID:28528741, PMID:28699257 NCBI chr14:50,083,079...50,165,528
Ensembl chr14:50,082,896...50,165,523
JBrowse link
G MAPK3 mitogen-activated protein kinase 3 multiple interactions
increases phosphorylation
EXP ochratoxin A inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]
ochratoxin A results in increased phosphorylation of MAPK3 protein
CTD PMID:28528741, PMID:28699257 NCBI chr 3:18,291,444...18,299,410
Ensembl chr 3:18,291,445...18,299,567
JBrowse link
G MTOR mechanistic target of rapamycin kinase decreases phosphorylation EXP ochratoxin A results in decreased phosphorylation of MTOR protein CTD PMID:30287338 NCBI chr 6:71,286,989...71,412,913
Ensembl chr 6:71,286,989...71,412,888
JBrowse link
G MYD88 MYD88 innate immune signal transduction adaptor multiple interactions EXP ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of MYD88 mRNA]; ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of MYD88 protein] CTD PMID:28528741 NCBI chr13:22,976,951...22,979,568
Ensembl chr13:22,964,071...22,983,109
JBrowse link
G NEIL1 nei like DNA glycosylase 1 decreases expression
multiple interactions
EXP ochratoxin A results in decreased expression of NEIL1 mRNA
alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [ochratoxin A results in decreased expression of NEIL1 mRNA]; Decitabine inhibits the reaction [ochratoxin A results in decreased expression of NEIL1 mRNA]; STAT3 protein affects the reaction [ochratoxin A results in decreased expression of NEIL1 mRNA]
CTD PMID:30923867 NCBI chr 7:58,261,761...58,269,001
Ensembl chr 7:58,261,761...58,283,092
JBrowse link
G NEIL3 nei like DNA glycosylase 3 multiple interactions
decreases expression
EXP alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [ochratoxin A results in decreased expression of NEIL3 mRNA]; Decitabine inhibits the reaction [ochratoxin A results in decreased expression of NEIL3 mRNA]; STAT3 protein affects the reaction [ochratoxin A results in decreased expression of NEIL3 mRNA] CTD PMID:30923867 NCBI chr15:39,416,073...39,632,313
Ensembl chr15:39,581,856...39,632,310
JBrowse link
G NFE2L2 nuclear factor, erythroid 2 like 2 decreases activity
multiple interactions
decreases expression
EXP ochratoxin A results in decreased activity of NFE2L2 protein
NFE2L2 protein affects the reaction [ochratoxin A results in increased expression of IL6 mRNA]; NFE2L2 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 mRNA]; NFE2L2 protein affects the reaction [ochratoxin A results in increased expression of TP53 protein]; ochratoxin A inhibits the reaction [sulforafan affects the localization of NFE2L2 protein]; ochratoxin A inhibits the reaction [sulforafan results in increased activity of NFE2L2 protein]; ochratoxin A inhibits the reaction [sulforafan results in increased expression of NFE2L2 mRNA]
ochratoxin A results in decreased expression of NFE2L2 mRNA
CTD PMID:18547363, PMID:18547704, PMID:28710020 NCBI chr15:82,967,485...83,146,185
Ensembl chr15:82,973,648...83,146,183
JBrowse link
G NPM1 nucleophosmin 1 increases expression EXP ochratoxin A results in increased expression of NPM1 mRNA CTD PMID:14994279 NCBI chr16:52,767,263...52,781,862
Ensembl chr16:52,765,296...52,781,740
JBrowse link
G OGG1 8-oxoguanine DNA glycosylase decreases expression
multiple interactions
EXP ochratoxin A results in decreased expression of OGG1 mRNA
alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [ochratoxin A results in decreased expression of OGG1 mRNA]; Decitabine inhibits the reaction [ochratoxin A results in decreased expression of OGG1 mRNA]; STAT3 protein affects the reaction [ochratoxin A results in decreased expression of OGG1 mRNA]
CTD PMID:30923867 NCBI chr13:66,038,669...66,045,478 JBrowse link
G PARP1 poly(ADP-ribose) polymerase 1 increases cleavage
increases expression
multiple interactions
EXP ochratoxin A results in increased cleavage of PARP1 protein
ochratoxin A results in increased expression of PARP1 protein
3-methyladenine promotes the reaction [ochratoxin A results in increased cleavage of PARP1 protein]; ATG5 protein affects the reaction [ochratoxin A results in increased cleavage of PARP1 protein]; BECN1 protein affects the reaction [ochratoxin A results in increased cleavage of PARP1 protein]; Chloroquine promotes the reaction [ochratoxin A results in increased cleavage of PARP1 protein]
CTD PMID:30287338, PMID:32454083 NCBI chr10:14,203,157...14,241,164
Ensembl chr10:14,203,159...14,241,197
JBrowse link
G PCK1 phosphoenolpyruvate carboxykinase 1 decreases expression EXP ochratoxin A results in decreased expression of PCK1 mRNA; ochratoxin A results in decreased expression of PCK1 protein CTD PMID:3753873 NCBI chr17:57,930,507...57,936,523
Ensembl chr17:57,930,432...57,938,896
JBrowse link
G PCNA proliferating cell nuclear antigen decreases expression EXP ochratoxin A results in decreased expression of PCNA protein CTD PMID:32454083 NCBI chr17:14,137,746...14,142,584
Ensembl chr17:14,125,814...14,185,276
JBrowse link
G PFDN5 prefoldin subunit 5 decreases expression EXP ochratoxin A results in decreased expression of PFDN5 mRNA CTD PMID:14994279 NCBI chr 5:18,512,637...18,516,928
Ensembl chr 5:18,512,719...18,525,877
JBrowse link
G PPIA peptidylprolyl isomerase A increases expression EXP ochratoxin A results in increased expression of PPIA mRNA CTD PMID:14994279 NCBI chr18:50,563,130...50,566,857 JBrowse link
G PRDX1 peroxiredoxin 1 decreases expression EXP ochratoxin A results in decreased expression of PRDX1 mRNA CTD PMID:14994279 NCBI chr 6:165,847,390...165,859,918
Ensembl chr 6:165,824,520...165,861,442
JBrowse link
G PTMA prothymosin alpha decreases expression EXP ochratoxin A results in decreased expression of PTMA mRNA CTD PMID:14994279 NCBI chr15:132,353,763...132,361,442
Ensembl chr15:132,355,655...132,361,435
JBrowse link
G RAD51 RAD51 recombinase increases expression EXP ochratoxin A results in increased expression of RAD51 protein CTD PMID:32454083 NCBI chr 1:130,592,414...130,640,326
Ensembl chr 1:130,586,647...130,640,136
JBrowse link
G RELA RELA proto-oncogene, NF-kB subunit multiple interactions EXP ochratoxin A inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein] CTD PMID:28528741 NCBI chr 2:6,594,869...6,602,684
Ensembl chr 2:6,593,969...6,603,471
JBrowse link
G RPA2 replication protein A2 increases expression EXP ochratoxin A results in increased expression of RPA2 protein CTD PMID:32454083 NCBI chr 6:85,032,604...85,045,899
Ensembl chr 6:85,031,578...85,045,916
JBrowse link
G RPS5 ribosomal protein S5 increases expression EXP ochratoxin A results in increased expression of RPS5 mRNA CTD PMID:14994279 NCBI chr 6:62,967,955...62,974,353
Ensembl chr 6:62,921,635...62,974,354
JBrowse link
G SOCS3 suppressor of cytokine signaling 3 increases expression
multiple interactions
EXP ochratoxin A results in increased expression of SOCS3 mRNA; ochratoxin A results in increased expression of SOCS3 protein
Decitabine promotes the reaction [ochratoxin A results in increased expression of SOCS3 mRNA]; Decitabine promotes the reaction [ochratoxin A results in increased expression of SOCS3 protein]
CTD PMID:30923867 NCBI chr12:3,643,832...3,647,015
Ensembl chr12:3,643,929...3,647,012
JBrowse link
G SOD1 superoxide dismutase 1 decreases activity EXP ochratoxin A results in decreased activity of SOD1 protein CTD PMID:18547704 NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,749
JBrowse link
G SQSTM1 sequestosome 1 multiple interactions
decreases expression
EXP Chloroquine inhibits the reaction [ochratoxin A results in decreased expression of SQSTM1 protein] CTD PMID:30287338 NCBI chr 2:78,752,768...78,763,998
Ensembl chr 2:78,752,768...78,784,256
JBrowse link
G STAT3 signal transducer and activator of transcription 3 multiple interactions
increases phosphorylation
EXP Decitabine inhibits the reaction [ochratoxin A results in increased phosphorylation of STAT3 protein]; STAT3 protein affects the reaction [ochratoxin A results in decreased expression of NEIL1 mRNA]; STAT3 protein affects the reaction [ochratoxin A results in decreased expression of NEIL3 mRNA]; STAT3 protein affects the reaction [ochratoxin A results in decreased expression of OGG1 mRNA]; STAT3 protein affects the reaction [ochratoxin A results in increased expression of H2AX protein] CTD PMID:30923867 NCBI chr12:20,407,316...20,471,091
Ensembl chr12:20,407,233...20,472,993
JBrowse link
G SUMO1 small ubiquitin like modifier 1 decreases expression EXP ochratoxin A results in decreased expression of SUMO1 mRNA CTD PMID:14994279 NCBI chr15:105,820,237...105,850,099
Ensembl chr15:105,815,281...105,850,943
JBrowse link
G TGFB1 transforming growth factor beta 1 increases expression
multiple interactions
EXP ochratoxin A results in increased expression of TGFB1 mRNA
NFE2L2 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 mRNA]; sulforafan inhibits the reaction [ochratoxin A results in increased expression of TGFB1 mRNA]
CTD PMID:28710020 NCBI chr 6:49,332,169...49,348,642
Ensembl chr 6:49,332,169...49,349,048
JBrowse link
G TIMP2 TIMP metallopeptidase inhibitor 2 increases expression EXP ochratoxin A results in increased expression of TIMP2 mRNA CTD PMID:14994279 NCBI chr12:3,254,794...3,300,835
Ensembl chr12:3,254,493...3,300,835
JBrowse link
G TJP1 tight junction protein 1 affects localization EXP ochratoxin A affects the localization of TJP1 protein CTD PMID:14994279 NCBI chr 1:144,930,387...145,195,857
Ensembl chr 1:144,930,368...145,195,836
JBrowse link
G TLR4 toll like receptor 4 multiple interactions EXP ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TLR4 mRNA]; ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TLR4 protein]; TLR4 protein affects the reaction [ochratoxin A affects the expression of BCL2 mRNA]; TLR4 protein affects the reaction [ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of IL1A mRNA]]; TLR4 protein affects the reaction [ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]] CTD PMID:28528741 NCBI chr 1:258,044,610...258,054,641
Ensembl chr 1:258,044,610...258,059,004
JBrowse link
G TNF tumor necrosis factor multiple interactions
increases secretion
EXP ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; TLR4 protein affects the reaction [ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]
ochratoxin A results in increased secretion of TNF protein
CTD PMID:28528741, PMID:28699257 NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,636...23,703,655
JBrowse link
G TP53 tumor protein p53 multiple interactions
increases expression
EXP NFE2L2 protein affects the reaction [ochratoxin A results in increased expression of TP53 protein] CTD PMID:28710020, PMID:32454083 NCBI chr12:52,939,643...52,953,786
Ensembl chr12:52,939,643...52,953,819
JBrowse link
G XPA XPA, DNA damage recognition and repair factor decreases expression EXP ochratoxin A results in decreased expression of XPA mRNA CTD PMID:14994279 NCBI chr 1:239,532,331...239,568,589
Ensembl chr 1:239,532,246...239,568,649
JBrowse link
G XRCC1 X-ray repair cross complementing 1 increases expression EXP ochratoxin A results in increased expression of XRCC1 protein CTD PMID:32454083 NCBI chr 6:50,403,691...50,425,730
Ensembl chr 6:50,403,686...50,425,710
JBrowse link
ochratoxin B term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G NFE2L2 nuclear factor, erythroid 2 like 2 decreases activity EXP ochratoxin B results in decreased activity of NFE2L2 protein CTD PMID:18547704 NCBI chr15:82,967,485...83,146,185
Ensembl chr15:82,973,648...83,146,183
JBrowse link
oleandrin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ATP1A1 ATPase Na+/K+ transporting subunit alpha 1 decreases activity EXP oleandrin results in decreased activity of ATP1A1 protein CTD PMID:28438630 NCBI chr 4:104,353,506...104,384,321
Ensembl chr 4:104,353,506...104,384,606
JBrowse link
G CASP3 caspase 3 decreases cleavage EXP oleandrin results in decreased cleavage of CASP3 protein CTD PMID:28438630 NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,749...45,763,773
JBrowse link
orlistat term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G PNLIP pancreatic lipase decreases activity EXP Orlistat results in decreased activity of PNLIP protein CTD PMID:21438711 NCBI chr14:126,771,920...126,789,097
Ensembl chr14:126,771,920...126,789,160
JBrowse link
oxytetracycline term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G SLCO1A2 solute carrier organic anion transporter family member 1A2 multiple interactions
increases uptake
EXP Oxytetracycline inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline]; Oxytetracycline inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; Oxytetracycline inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]
SLCO1A2 protein results in increased uptake of Oxytetracycline
CTD PMID:31287969 NCBI chr 5:52,020,303...52,133,132
Ensembl chr 5:52,037,218...52,131,789
JBrowse link
p-xylene term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CASP3 caspase 3 increases activity
multiple interactions
affects response to substance
EXP 4-xylene results in increased activity of CASP3 protein
aspartyl-glutamyl-valyl-aspartal inhibits the reaction [4-xylene results in increased activity of CASP3 protein]
CASP3 protein affects the susceptibility to 4-xylene
CTD PMID:14705839 NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,749...45,763,773
JBrowse link
G CAT catalase multiple interactions EXP CAT protein inhibits the reaction [4-xylene results in increased secretion of Malondialdehyde] CTD PMID:12781212 NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452
JBrowse link
G CYP2E1 cytochrome P450, family 2, subfamily E, polypeptide 1 increases activity
multiple interactions
EXP 4-xylene results in increased activity of CYP2E1 protein
Disulfiram inhibits the reaction [4-xylene results in increased activity of CYP2E1 protein]
CTD PMID:12781212 NCBI chr14:141,690,737...141,703,078
Ensembl chr14:141,690,426...141,736,818
JBrowse link
phorbol 13-acetate 12-myristate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CXCL8 C-X-C motif chemokine ligand 8 multiple interactions EXP [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of CXCL8 protein CTD PMID:15912099 NCBI chr 8:69,932,646...69,935,861
Ensembl chr 8:69,932,643...69,935,861
JBrowse link
G EDN1 endothelin 1 multiple interactions
increases expression
EXP Clofibrate inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EDN1 protein] CTD PMID:17105827 NCBI chr 7:8,752,018...8,758,354
Ensembl chr 7:8,751,695...8,758,348
JBrowse link
G MAPK1 mitogen-activated protein kinase 1 increases phosphorylation EXP Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK1 protein CTD PMID:11325585 NCBI chr14:50,083,079...50,165,528
Ensembl chr14:50,082,896...50,165,523
JBrowse link
G MAPK3 mitogen-activated protein kinase 3 increases phosphorylation EXP Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK3 protein CTD PMID:11325585 NCBI chr 3:18,291,444...18,299,410
Ensembl chr 3:18,291,445...18,299,567
JBrowse link
G MAPK9 mitogen-activated protein kinase 9 increases phosphorylation EXP Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK9 protein CTD PMID:11325585 NCBI chr 2:78,338,466...78,399,108
Ensembl chr 2:78,338,369...78,399,105
JBrowse link
G PPARA peroxisome proliferator activated receptor alpha decreases expression
multiple interactions
EXP Tetradecanoylphorbol Acetate results in decreased expression of PPARA; Tetradecanoylphorbol Acetate results in decreased expression of PPARA protein
calphostin C promotes the reaction [Tetradecanoylphorbol Acetate results in decreased expression of PPARA]; Tetradecanoylphorbol Acetate inhibits the reaction [Clofibrate results in increased expression of PPARA]
CTD PMID:17105827, PMID:20568414 NCBI chr 5:3,302,755...3,321,091
Ensembl chr 5:3,300,708...3,366,361
JBrowse link
G PRKCB protein kinase C beta decreases phosphorylation EXP Tetradecanoylphorbol Acetate results in decreased phosphorylation of PRKCB protein CTD PMID:15089098 NCBI chr 3:21,995,227...22,383,628
Ensembl chr 3:21,995,231...22,383,264
JBrowse link
G PRKCD protein kinase C delta increases phosphorylation EXP Tetradecanoylphorbol Acetate results in increased phosphorylation of PRKCD protein CTD PMID:15089098 NCBI chr13:35,290,835...35,323,245
Ensembl chr13:35,290,264...35,323,356
JBrowse link
G SELE selectin E increases expression EXP Tetradecanoylphorbol Acetate results in increased expression of SELE protein CTD PMID:16797888 NCBI chr 4:81,289,061...81,299,657 JBrowse link
G SELP selectin P increases expression EXP Tetradecanoylphorbol Acetate results in increased expression of SELP protein CTD PMID:16797888 NCBI chr 4:81,376,804...81,401,240
Ensembl chr 4:81,365,740...81,406,203
JBrowse link
G VCAM1 vascular cell adhesion molecule 1 increases expression EXP Tetradecanoylphorbol Acetate results in increased expression of VCAM1 protein CTD PMID:16797888 NCBI chr 4:117,496,914...117,511,211
Ensembl chr 4:117,496,908...117,511,226
JBrowse link
pregnenolone term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G GHRL ghrelin and obestatin prepropeptide decreases metabolic processing EXP GHRL protein results in decreased metabolism of Pregnenolone CTD PMID:22341706 NCBI chr13:66,442,106...66,453,576
Ensembl chr13:66,316,436...66,452,917
JBrowse link
progesterone term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G AGT angiotensinogen increases secretion EXP AGT protein results in increased secretion of Progesterone CTD PMID:22100847 NCBI chr14:59,643,030...59,656,835
Ensembl chr14:59,643,292...59,672,428
JBrowse link
G CRABP1 cellular retinoic acid binding protein 1 affects expression EXP Progesterone affects the expression of CRABP1 protein CTD PMID:11833939 NCBI chr 7:47,602,316...47,608,865
Ensembl chr 7:47,602,192...47,608,970
JBrowse link
G CST3 cystatin C affects expression EXP Progesterone affects the expression of CST3 mRNA CTD PMID:20107207 NCBI chr17:30,471,056...30,474,486
Ensembl chr17:30,470,855...30,474,590
JBrowse link
G CTSB cathepsin B increases expression EXP Progesterone results in increased expression of CTSB mRNA CTD PMID:20107207 NCBI chr14:15,014,139...15,035,081
Ensembl chr14:15,011,711...15,034,737
JBrowse link
G CTSL cathepsin L increases expression EXP Progesterone results in increased expression of CTSL mRNA CTD PMID:20107207 NCBI chr10:27,668,523...27,674,705
Ensembl chr10:27,668,264...27,674,618
JBrowse link
G EGFR epidermal growth factor receptor affects chemical synthesis EXP EGFR protein affects the chemical synthesis of Progesterone CTD PMID:21520325 NCBI chr 9:139,302,410...139,474,632
Ensembl chr 9:139,300,022...139,478,882
JBrowse link
G FGF2 fibroblast growth factor 2 multiple interactions EXP Progesterone inhibits the reaction [estrone benzoate results in decreased expression of FGF2 mRNA] CTD PMID:15120423 NCBI chr 8:101,278,877...101,344,084
Ensembl chr 8:101,278,878...101,343,916
JBrowse link
G FGFR1 fibroblast growth factor receptor 1 multiple interactions
decreases expression
EXP estrone benzoate inhibits the reaction [Progesterone results in decreased expression of FGFR1 mRNA alternative form] CTD PMID:15120423 NCBI chr15:48,053,895...48,106,634
Ensembl chr15:48,053,340...48,106,746
JBrowse link
G FGFR2 fibroblast growth factor receptor 2 decreases expression
multiple interactions
EXP Progesterone results in decreased expression of FGFR2 mRNA alternative form
[Progesterone co-treated with estradiol 3-benzoate] results in decreased expression of FGFR2 mRNA alternative form
CTD PMID:15120423, PMID:15976484 NCBI chr14:131,183,095...131,285,001
Ensembl chr14:131,181,710...131,579,703
JBrowse link
G FSHB follicle stimulating hormone subunit beta increases chemical synthesis
increases abundance
multiple interactions
EXP FSHB protein results in increased chemical synthesis of Progesterone
FSHB protein results in increased abundance of Progesterone
[FSHB protein co-treated with IGF1 protein] results in increased abundance of Progesterone; [FSHB protein co-treated with Lead co-treated with Mercury] results in decreased secretion of Progesterone; bisphenol A inhibits the reaction [FSHB protein results in increased chemical synthesis of and results in increased secretion of Progesterone]; bisphenol A promotes the reaction [fisetin inhibits the reaction [FSHB protein results in increased chemical synthesis of and results in increased secretion of Progesterone]]; deoxynivalenol inhibits the reaction [[FSHB protein co-treated with IGF1 protein] results in increased abundance of Progesterone]; fisetin inhibits the reaction [FSHB protein results in increased chemical synthesis of and results in increased secretion of Progesterone]; fisetin promotes the reaction [bisphenol A inhibits the reaction [FSHB protein results in increased chemical synthesis of and results in increased secretion of Progesterone]]; FSHB protein results in increased chemical synthesis of and results in increased secretion of Progesterone; Lapatinib inhibits the reaction [FSHB protein results in increased abundance of Progesterone]; Zearalenone promotes the reaction [FSHB protein results in increased abundance of Progesterone]
CTD PMID:17656051, PMID:20390873, PMID:20965553, PMID:23375200, PMID:29544186 NCBI chr 2:30,395,769...30,399,282
Ensembl chr 2:30,395,018...30,399,274
JBrowse link
G GHRL ghrelin and obestatin prepropeptide multiple interactions
decreases secretion
increases secretion
EXP Aminoglutethimide promotes the reaction [GHRL protein results in decreased secretion of Progesterone]; GHRL protein results in decreased chemical synthesis of and results in decreased secretion of Progesterone; STAT1 protein inhibits the reaction [GHRL protein results in decreased secretion of Progesterone]
GHRL protein results in increased secretion of Progesterone
CTD PMID:17904772, PMID:19528263, PMID:22341706 NCBI chr13:66,442,106...66,453,576
Ensembl chr13:66,316,436...66,452,917
JBrowse link
G HOXA10 homeobox A10 increases expression
multiple interactions
EXP Progesterone results in increased expression of HOXA10 mRNA
Estradiol promotes the reaction [Progesterone results in increased expression of HOXA10 mRNA]
CTD PMID:21705055 NCBI chr18:45,393,525...45,403,259
Ensembl chr18:45,393,712...45,403,257
JBrowse link
G IGF1 insulin like growth factor 1 multiple interactions
increases abundance
EXP [FSHB protein co-treated with IGF1 protein] results in increased abundance of Progesterone; deoxynivalenol inhibits the reaction [[FSHB protein co-treated with IGF1 protein] results in increased abundance of Progesterone]; Zearalenone promotes the reaction [IGF1 protein results in increased abundance of Progesterone] CTD PMID:17656051 NCBI chr 5:81,762,027...81,909,253
Ensembl chr 5:81,775,970...81,848,037
JBrowse link
G LEP leptin multiple interactions
increases expression
increases secretion
EXP [TP53 protein co-treated with LEP protein] results in increased secretion of Progesterone
Progesterone results in increased expression of LEP mRNA
Progesterone results in increased secretion of LEP protein
CTD PMID:22151798, PMID:23153703 NCBI chr18:20,106,867...20,124,071
Ensembl chr18:20,106,868...20,123,447
JBrowse link
G LHB luteinizing hormone subunit beta increases abundance
multiple interactions
EXP LHB protein results in increased abundance of Progesterone
daidzein inhibits the reaction [LHB protein results in increased abundance of Progesterone]; Lapatinib inhibits the reaction [LHB protein results in increased abundance of Progesterone]
CTD PMID:19617652, PMID:23375200 NCBI chr 6:54,263,574...54,269,286 JBrowse link
G OXT oxytocin/neurophysin I prepropeptide multiple interactions EXP Progesterone affects the reaction [OXT protein results in increased abundance of Calcium]; Progesterone inhibits the reaction [OXT protein results in increased abundance of Dinoprost]; Progesterone inhibits the reaction [OXT protein results in increased secretion of Dinoprost]; Progesterone inhibits the reaction [OXT protein results in increased secretion of Dinoprostone]; Progesterone inhibits the reaction [OXT protein results in increased transport of Calcium] CTD PMID:16997130, PMID:21370738 NCBI chr17:32,605,586...32,606,449
Ensembl chr17:32,605,588...32,606,483
JBrowse link
G PLAU plasminogen activator, urokinase increases expression EXP Progesterone results in increased expression of PLAU mRNA CTD PMID:23103014 NCBI chr14:76,629,313...76,635,173
Ensembl chr14:76,629,299...76,635,172
JBrowse link
G POMC proopiomelanocortin increases secretion EXP POMC protein results in increased secretion of Progesterone CTD PMID:22100847 NCBI chr 3:113,661,712...113,668,558 JBrowse link
G RBP4 retinol binding protein 4 affects expression EXP Progesterone affects the expression of RBP4 protein CTD PMID:11833939 NCBI chr14:105,037,360...105,044,552
Ensembl chr14:105,036,770...105,044,765
JBrowse link
G STAT1 signal transducer and activator of transcription 1 multiple interactions EXP STAT1 protein inhibits the reaction [GHRL protein results in decreased secretion of Progesterone] CTD PMID:19528263 NCBI chr15:95,593,201...95,646,324
Ensembl chr15:95,593,211...95,646,260
JBrowse link
G TP53 tumor protein p53 multiple interactions
decreases secretion
EXP [TP53 protein co-treated with LEP protein] results in increased secretion of Progesterone
TP53 protein results in decreased secretion of Progesterone
CTD PMID:22151798 NCBI chr12:52,939,643...52,953,786
Ensembl chr12:52,939,643...52,953,819
JBrowse link
ritonavir term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G NOS3 nitric oxide synthase 3 multiple interactions
decreases expression
EXP Masoprocol inhibits the reaction [Ritonavir results in decreased expression of NOS3 mRNA]; Masoprocol inhibits the reaction [Ritonavir results in decreased expression of NOS3 protein]; Ritonavir results in decreased expression of and results in decreased activity of NOS3 protein
Ritonavir results in decreased expression of NOS3 mRNA; Ritonavir results in decreased expression of NOS3 protein
CTD PMID:15681703, PMID:16123675, PMID:22037733 NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,156...6,228,938
JBrowse link
sinefungin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G COMT catechol-O-methyltransferase decreases activity EXP sinefungin results in decreased activity of COMT protein CTD PMID:26577531 NCBI chr14:51,384,729...51,403,997
Ensembl chr14:51,385,133...51,403,998
JBrowse link
strychnine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CHRM2 cholinergic receptor muscarinic 2 multiple interactions EXP Strychnine analog promotes the reaction [N-Methylscopolamine binds to CHRM2 protein] CTD PMID:12757728 NCBI chr18:12,455,139...12,600,314
Ensembl chr18:12,455,150...12,600,249
JBrowse link
tamoxifen term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ESR1 estrogen receptor 1 affects binding EXP Tamoxifen metabolite binds to ESR1 protein CTD PMID:16790557 NCBI chr 1:14,217,032...14,604,906
Ensembl chr 1:14,217,036...14,493,363
JBrowse link
Tanshinone I term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G AGT angiotensinogen multiple interactions EXP tanshinone inhibits the reaction [AGT protein results in decreased expression of NOS3 mRNA]; tanshinone inhibits the reaction [AGT protein results in decreased expression of NOS3 protein] CTD PMID:17717927 NCBI chr14:59,643,030...59,656,835
Ensembl chr14:59,643,292...59,672,428
JBrowse link
G NOS3 nitric oxide synthase 3 multiple interactions EXP tanshinone inhibits the reaction [AGT protein results in decreased expression of NOS3 mRNA]; tanshinone inhibits the reaction [AGT protein results in decreased expression of NOS3 protein] CTD PMID:17717927 NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,156...6,228,938
JBrowse link
taurocholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCB11 ATP binding cassette subfamily B member 11 increases transport EXP ABCB11 protein results in increased transport of Taurocholic Acid CTD PMID:21056966 NCBI chr15:75,402,296...75,487,092
Ensembl chr15:75,400,766...75,486,403
JBrowse link
G SLCO1A2 solute carrier organic anion transporter family member 1A2 increases uptake
multiple interactions
EXP SLCO1A2 protein results in increased uptake of Taurocholic Acid
Amoxicillin inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; cefquinome inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; Clarithromycin inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; daidzein inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; Doxycycline inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; epigallocatechin gallate inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; Erythromycin inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; Genistein inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; naringin inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; Oxytetracycline inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; Penicillins inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; Tetracycline inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; tilmicosin inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; Tylosin inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]
CTD PMID:31287969 NCBI chr 5:52,020,303...52,133,132
Ensembl chr 5:52,037,218...52,131,789
JBrowse link
testosterone term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ADIPOQ adiponectin, C1Q and collagen domain containing multiple interactions
increases secretion
EXP 2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [ADIPOQ protein results in increased secretion of Testosterone]; bisphenol A inhibits the reaction [ADIPOQ protein results in increased secretion of Testosterone]; halowax 1051 promotes the reaction [ADIPOQ protein results in increased secretion of Testosterone]; Testosterone results in decreased expression of and results in decreased secretion of ADIPOQ protein CTD PMID:28284726 NCBI chr13:124,633,906...124,646,237
Ensembl chr13:124,633,684...124,646,648
JBrowse link
G ADIPOR1 adiponectin receptor 1 decreases expression EXP Testosterone results in decreased expression of ADIPOR1 protein CTD PMID:28284726 NCBI chr10:24,907,491...24,923,540 JBrowse link
G ADIPOR2 adiponectin receptor 2 decreases expression EXP Testosterone results in decreased expression of ADIPOR2 protein CTD PMID:28284726 NCBI chr 5:68,755,789...68,807,247
Ensembl chr 5:68,755,811...68,807,235
JBrowse link
G CYP19A2 cytochrome P450 19A2 multiple interactions EXP [2,4,5,2',4',5'-hexachlorobiphenyl co-treated with Testosterone] affects the activity of CYP19A1 protein; [3,4,5,3',4'-pentachlorobiphenyl co-treated with Testosterone] results in increased activity of CYP19A1 protein CTD PMID:16151981 NCBI chr 1:120,652,172...120,695,899
Ensembl chr 1:120,367,667...120,695,899
JBrowse link
G CYP3A29 cytochrome P450 3A29 multiple interactions
increases hydroxylation
EXP Ketoconazole inhibits the reaction [CYP3A29 protein results in increased hydroxylation of Testosterone]; Troleandomycin inhibits the reaction [CYP3A29 protein results in increased hydroxylation of Testosterone] CTD PMID:20863320 NCBI chr 3:6,738,502...6,778,121 JBrowse link
G INS insulin multiple interactions EXP 9-deoxy-delta-9-prostaglandin D2 inhibits the reaction [[LHB protein co-treated with INS protein] results in increased abundance of Testosterone]; [LHB protein co-treated with INS protein] results in increased abundance of Testosterone; Troglitazone inhibits the reaction [[LHB protein co-treated with INS protein] results in increased abundance of Testosterone] CTD PMID:11889176 NCBI chr 2:1,496,842...1,498,052
Ensembl chr 2:1,496,842...1,497,841
JBrowse link
G LHB luteinizing hormone subunit beta increases secretion
multiple interactions
EXP LHB protein results in increased secretion of Testosterone
9-deoxy-delta-9-prostaglandin D2 inhibits the reaction [[LHB protein co-treated with INS protein] results in increased abundance of Testosterone]; [LHB protein co-treated with INS protein] results in increased abundance of Testosterone; Biological Products inhibits the reaction [LHB protein results in increased secretion of Testosterone]; Cod Liver Oil inhibits the reaction [LHB protein results in increased secretion of Testosterone]; Industrial Waste inhibits the reaction [LHB protein results in increased secretion of Testosterone]; Troglitazone inhibits the reaction [[LHB protein co-treated with INS protein] results in increased abundance of Testosterone]
CTD PMID:11889176, PMID:26055946 NCBI chr 6:54,263,574...54,269,286 JBrowse link
tetracycline term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G SLCO1A2 solute carrier organic anion transporter family member 1A2 increases uptake
multiple interactions
EXP SLCO1A2 protein results in increased uptake of Tetracycline
Tetracycline inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; Tetracycline inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]
CTD PMID:31287969 NCBI chr 5:52,020,303...52,133,132
Ensembl chr 5:52,037,218...52,131,789
JBrowse link
thapsigargin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G HSP90B1 heat shock protein 90 beta family member 1 increases expression
multiple interactions
decreases expression
increases cleavage
EXP Thapsigargin results in increased expression of HSP90B1 protein
PD 150606 inhibits the reaction [Thapsigargin results in increased cleavage of HSP90B1 protein]
Thapsigargin results in decreased expression of HSP90B1 protein
CTD PMID:16759985, PMID:16920763, PMID:17416481 NCBI chr 5:80,511,513...80,531,016
Ensembl chr 5:80,511,507...80,531,005
JBrowse link
G HSPA5 heat shock protein family A (Hsp70) member 5 increases expression EXP Thapsigargin results in increased expression of HSPA5 protein CTD PMID:16759985, PMID:16920763, PMID:17416481 NCBI chr 1:265,930,044...265,934,959
Ensembl chr 1:265,930,045...265,934,904
JBrowse link
thymol term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G RYR1 ryanodine receptor 1 increases activity EXP Thymol results in increased activity of RYR1 protein CTD PMID:17641978 NCBI chr 6:47,339,759...47,458,457 JBrowse link
thymol sulfate(1-) term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G RYR1 ryanodine receptor 1 increases activity EXP Thymol results in increased activity of RYR1 protein CTD PMID:17641978 NCBI chr 6:47,339,759...47,458,457 JBrowse link
toluene term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CASP3 caspase 3 increases activity
affects response to substance
multiple interactions
EXP Toluene results in increased activity of CASP3 protein
CASP3 protein affects the susceptibility to Toluene
aspartyl-glutamyl-valyl-aspartal inhibits the reaction [Toluene results in increased activity of CASP3 protein]
CTD PMID:14705839 NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,749...45,763,773
JBrowse link
G CAT catalase multiple interactions EXP CAT protein inhibits the reaction [Toluene results in increased secretion of Malondialdehyde] CTD PMID:12781212 NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452
JBrowse link
G CYP2E1 cytochrome P450, family 2, subfamily E, polypeptide 1 multiple interactions
increases activity
EXP Disulfiram inhibits the reaction [Toluene results in increased activity of CYP2E1 protein] CTD PMID:12781212 NCBI chr14:141,690,737...141,703,078
Ensembl chr14:141,690,426...141,736,818
JBrowse link
troleandomycin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CYP3A29 cytochrome P450 3A29 multiple interactions EXP Troleandomycin inhibits the reaction [CYP3A29 protein results in increased chemical synthesis of 6 beta-hydroxytestosterone]; Troleandomycin inhibits the reaction [CYP3A29 protein results in increased hydroxylation of Testosterone]; Troleandomycin inhibits the reaction [CYP3A29 protein results in increased oxidation of Nifedipine] CTD PMID:20863320 NCBI chr 3:6,738,502...6,778,121 JBrowse link
tubocurarine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G TAC1 tachykinin precursor 1 affects activity EXP Tubocurarine affects the activity of TAC1 protein CTD PMID:11877319 NCBI chr 9:77,197,403...77,206,529
Ensembl chr 9:77,197,535...77,206,526
JBrowse link
zileuton term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ALOX5 arachidonate 5-lipoxygenase decreases activity EXP zileuton results in decreased activity of ALOX5 protein CTD PMID:11509739 NCBI chr14:90,859,209...90,907,084
Ensembl chr14:90,858,975...90,907,094
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 880
    chemical entity 880
      molecular entity 878
        polyatomic entity 843
          heteroatomic molecular entity 799
            hydrides 345
              organic hydride 243
                organic fundamental parent + 243
Path 2
Term Annotations click to browse term
  CHEBI ontology 880
    subatomic particle 865
      composite particle 865
        hadron 865
          baryon 865
            nucleon 865
              atomic nucleus 865
                atom 865
                  main group element atom 855
                    main group molecular entity 853
                      s-block molecular entity 734
                        hydrogen molecular entity 721
                          hydrides 345
                            organic hydride 243
                              organic fundamental parent + 243
paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.